Carcinogenic human papillomavirus infection
Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause — if not controlled immunologically or by screening — virtu...
Saved in:
| Published in | Nature reviews. Disease primers Vol. 2; no. 1; p. 16086 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.12.2016
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2056-676X 2056-676X |
| DOI | 10.1038/nrdp.2016.86 |
Cover
| Abstract | Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause — if not controlled immunologically or by screening — virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge.
Virtually all cervical cancers, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers are caused by human papillomavirus (HPV) infection. Here, the authors describe HPV-driven carcinogenesis and discuss how developments in vaccines and screening tests could dramatically alter the landscape of HPV-related cancers worldwide. |
|---|---|
| AbstractList | Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause - if not controlled immunologically or by screening - virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge. Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause - if not controlled immunologically or by screening - virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge.Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause - if not controlled immunologically or by screening - virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge. Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause — if not controlled immunologically or by screening — virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge.Virtually all cervical cancers, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers are caused by human papillomavirus (HPV) infection. Here, the authors describe HPV-driven carcinogenesis and discuss how developments in vaccines and screening tests could dramatically alter the landscape of HPV-related cancers worldwide. Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause — if not controlled immunologically or by screening — virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge. Virtually all cervical cancers, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers are caused by human papillomavirus (HPV) infection. Here, the authors describe HPV-driven carcinogenesis and discuss how developments in vaccines and screening tests could dramatically alter the landscape of HPV-related cancers worldwide. |
| ArticleNumber | 16086 |
| Author | Franceschi, Silvia Wentzensen, Nicolas de Sanjosé, Silvia Monk, Bradley J. Schiffman, Mark Fakhry, Carole Doorbar, John Stanley, Margaret A. |
| Author_xml | – sequence: 1 givenname: Mark surname: Schiffman fullname: Schiffman, Mark email: schiffmm@mail.nih.gov organization: Division of Cancer Epidemiology and Genetics, National Cancer Institute – sequence: 2 givenname: John surname: Doorbar fullname: Doorbar, John organization: Department of Pathology, University of Cambridge – sequence: 3 givenname: Nicolas surname: Wentzensen fullname: Wentzensen, Nicolas organization: Division of Cancer Epidemiology and Genetics, National Cancer Institute – sequence: 4 givenname: Silvia surname: de Sanjosé fullname: de Sanjosé, Silvia organization: Catalan Institute of Oncology, IDIBELL, Cancer Epidemiology Research Programme and CIBER Epidemiologia Y Salud Publica – sequence: 5 givenname: Carole surname: Fakhry fullname: Fakhry, Carole organization: Department of Otolaryngology, Johns Hopkins Medicine – sequence: 6 givenname: Bradley J. surname: Monk fullname: Monk, Bradley J. organization: Division of Gynecologic Oncology, US Oncology Network, University of Arizona-Phoenix – sequence: 7 givenname: Margaret A. surname: Stanley fullname: Stanley, Margaret A. organization: Department of Pathology, University of Cambridge – sequence: 8 givenname: Silvia surname: Franceschi fullname: Franceschi, Silvia organization: International Agency for Research on Cancer, Infections and Cancer Epidemiology Group |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27905473$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10EtLw0AQB_BFFFtrb56l4EXQ1H0ku8lRii8oeFHwtuxuJnVLsom7ieC3N6H1QVHmMHP4zTD8j9C-qx0gdELwnGCWXjmfN3OKCZ-nfA-NKU54xAV_2f81j9A0hDXGmCQpz1J-iEZUZDiJBRuji4Xyxrp6Bc6a2WtXKTdrVGPLsq7Uu_VdmFlXgGlt7Y7RQaHKANNtn6Dn25unxX20fLx7WFwvIxNT1kZFkus0Y3ECGIoMAwfOjSZpnom8IEyTnFOiGS8E1TwzMS8yoRmGmGnQMQU2Qeebu42v3zoIraxsMFCWykHdBUnSOKF9CdrTsx26rjvv-u8kFYTgTGAc9-p0qzpdQS4bbyvlP-RXDD243ADj6xA8FN-EYDkELYeg5RC0THnP6Q43tlVDRK1XtvxvKdoshf62W4H_efVP_wmSeY9q |
| CitedBy_id | crossref_primary_10_1016_j_cell_2021_06_004 crossref_primary_10_1097_GRF_0000000000000789 crossref_primary_10_23736_S2724_606X_22_05102_8 crossref_primary_10_1002_ijc_32919 crossref_primary_10_1186_s12916_020_01613_x crossref_primary_10_3389_fcimb_2022_926348 crossref_primary_10_3390_vaccines8020181 crossref_primary_10_1080_2162402X_2018_1524694 crossref_primary_10_1111_his_13980 crossref_primary_10_1002_cncy_22895 crossref_primary_10_1016_j_abd_2020_11_003 crossref_primary_10_1007_s40944_025_00966_6 crossref_primary_10_1111_php_14038 crossref_primary_10_3389_fimmu_2021_805695 crossref_primary_10_3390_medicina60060922 crossref_primary_10_1128_spectrum_02253_24 crossref_primary_10_1371_journal_ppat_1008376 crossref_primary_10_1002_1878_0261_13661 crossref_primary_10_1016_j_ad_2022_08_014 crossref_primary_10_22207_JPAM_19_1_14 crossref_primary_10_3389_fbioe_2022_984166 crossref_primary_10_1016_j_canlet_2019_01_033 crossref_primary_10_2147_OTT_S475132 crossref_primary_10_1016_j_ypmed_2017_09_010 crossref_primary_10_1186_s12985_023_02114_y crossref_primary_10_1038_s41379_018_0101_z crossref_primary_10_1002_cncy_22877 crossref_primary_10_1016_j_eururo_2024_03_038 crossref_primary_10_1097_MD_0000000000037717 crossref_primary_10_1080_2162402X_2017_1336594 crossref_primary_10_3390_ijms23169241 crossref_primary_10_1002_dc_25064 crossref_primary_10_1016_j_whi_2024_01_001 crossref_primary_10_3389_fimmu_2022_918528 crossref_primary_10_1017_erm_2024_30 crossref_primary_10_1136_ijgc_2024_005579 crossref_primary_10_1371_journal_pone_0205933 crossref_primary_10_2174_1389450123666211221160632 crossref_primary_10_1111_cyt_12835 crossref_primary_10_17352_jgro_000117 crossref_primary_10_1371_journal_ppat_1007156 crossref_primary_10_1371_journal_ppat_1010444 crossref_primary_10_1016_j_ijbiomac_2018_12_235 crossref_primary_10_3892_ijo_2020_5039 crossref_primary_10_1016_j_ygyno_2019_04_680 crossref_primary_10_2139_ssrn_4194535 crossref_primary_10_1002_ijgo_13553 crossref_primary_10_1016_j_jmb_2022_167889 crossref_primary_10_3390_vaccines11020443 crossref_primary_10_1093_nar_gky227 crossref_primary_10_1111_josh_13311 crossref_primary_10_1016_j_vacun_2023_05_001 crossref_primary_10_1002_ccr3_3950 crossref_primary_10_1016_j_modpat_2023_100250 crossref_primary_10_1007_s00705_021_05317_2 crossref_primary_10_3389_pore_2022_1610176 crossref_primary_10_15448_1980_6108_2023_1_43033 crossref_primary_10_18027_2224_5057_2021_11_4_39_47 crossref_primary_10_1016_j_crtox_2022_100088 crossref_primary_10_3390_microorganisms12091897 crossref_primary_10_3390_pathogens12050636 crossref_primary_10_1097_GRF_0000000000000793 crossref_primary_10_3390_diagnostics14060611 crossref_primary_10_3390_v9080206 crossref_primary_10_3389_fnut_2022_899137 crossref_primary_10_18632_oncotarget_27756 crossref_primary_10_1128_JVI_01236_20 crossref_primary_10_1093_lambio_ovae045 crossref_primary_10_1016_S0140_6736_24_01547_2 crossref_primary_10_3390_cancers14061508 crossref_primary_10_3390_cancers14010193 crossref_primary_10_3390_v9090254 crossref_primary_10_1016_j_bpobgyn_2017_08_015 crossref_primary_10_3389_fonc_2018_00099 crossref_primary_10_1002_jmv_29068 crossref_primary_10_3390_cells12081131 crossref_primary_10_3389_fcimb_2024_1359367 crossref_primary_10_3802_jgo_2019_30_e55 crossref_primary_10_1080_15548627_2020_1847444 crossref_primary_10_1007_s00428_019_02694_7 crossref_primary_10_1038_s41598_025_90024_0 crossref_primary_10_1158_0008_5472_CAN_20_0029 crossref_primary_10_3390_v13101948 crossref_primary_10_1002_gcc_22702 crossref_primary_10_1016_j_hoc_2021_05_010 crossref_primary_10_1016_j_anpedi_2017_12_013 crossref_primary_10_1016_j_cegh_2021_100839 crossref_primary_10_1128_mBio_01163_21 crossref_primary_10_36384_01232576_431 crossref_primary_10_1016_j_virusres_2020_198004 crossref_primary_10_1016_j_transproceed_2024_04_009 crossref_primary_10_1158_1055_9965_EPI_18_0287 crossref_primary_10_1186_s12885_023_11759_5 crossref_primary_10_1002_ijc_31633 crossref_primary_10_3390_vaccines12010046 crossref_primary_10_3390_biology11081114 crossref_primary_10_3390_ijms26031296 crossref_primary_10_3390_pathogens9060467 crossref_primary_10_3389_fcimb_2020_00234 crossref_primary_10_3389_fcimb_2022_814948 crossref_primary_10_1016_j_virol_2018_05_019 crossref_primary_10_1186_s13046_020_01602_1 crossref_primary_10_3390_microorganisms11061417 crossref_primary_10_1371_journal_pone_0258539 crossref_primary_10_3390_ijms22179657 crossref_primary_10_1111_cas_15246 crossref_primary_10_3390_pharmaceutics13122057 crossref_primary_10_1016_j_celrep_2022_111546 crossref_primary_10_3390_pathogens14030293 crossref_primary_10_1007_s00210_024_03175_8 crossref_primary_10_1371_journal_ppat_1007352 crossref_primary_10_1016_j_cct_2020_105996 crossref_primary_10_1186_s13027_022_00467_7 crossref_primary_10_3389_fimmu_2023_1072655 crossref_primary_10_3390_vaccines12010016 crossref_primary_10_17116_repro2021270610 crossref_primary_10_1158_1078_0432_CCR_20_0776 crossref_primary_10_3390_jcm10071525 crossref_primary_10_1002_ijc_31409 crossref_primary_10_1007_s40944_022_00702_4 crossref_primary_10_15406_jcpcr_2021_12_00477 crossref_primary_10_1097_PAS_0000000000001862 crossref_primary_10_23736_S0026_4784_19_04443_5 crossref_primary_10_3390_vaccines9080921 crossref_primary_10_1159_000489386 crossref_primary_10_1016_S0140_6736_19_30549_5 crossref_primary_10_1038_s41416_020_01184_x crossref_primary_10_1016_j_anpede_2017_12_004 crossref_primary_10_3389_fpubh_2024_1421774 crossref_primary_10_3390_v13091846 crossref_primary_10_3390_curroncol30060425 crossref_primary_10_3390_ijms22031400 crossref_primary_10_1016_j_virusres_2020_198040 crossref_primary_10_1136_bmjopen_2017_015867 crossref_primary_10_1200_EDBK_325319 crossref_primary_10_1038_s41416_021_01419_5 crossref_primary_10_1093_jnci_djac034 crossref_primary_10_1186_s12879_019_4677_9 crossref_primary_10_1038_s41556_018_0042_2 crossref_primary_10_1016_j_prp_2018_08_032 crossref_primary_10_1128_jvi_00063_23 crossref_primary_10_1093_jnci_djac035 crossref_primary_10_3390_s22155489 crossref_primary_10_1088_1757_899X_864_1_012167 crossref_primary_10_1515_hsz_2019_0408 crossref_primary_10_7759_cureus_21961 crossref_primary_10_1177_1534735419893063 crossref_primary_10_1055_s_0043_1770134 crossref_primary_10_1002_cncr_35655 crossref_primary_10_1186_s13027_023_00498_8 crossref_primary_10_17116_repro20212706170 crossref_primary_10_1016_j_pvr_2020_100196 crossref_primary_10_1002_dc_23821 crossref_primary_10_1111_jog_14404 crossref_primary_10_3389_fcimb_2020_00307 crossref_primary_10_1093_infdis_jiz401 crossref_primary_10_3390_v15102104 crossref_primary_10_3390_cancers12102803 crossref_primary_10_3390_jpm13030567 crossref_primary_10_3390_women4010004 crossref_primary_10_1002_jmv_27012 crossref_primary_10_1016_j_jiph_2018_06_005 crossref_primary_10_1158_1078_0432_CCR_17_1553 crossref_primary_10_1038_s41467_020_14730_1 crossref_primary_10_1080_17460794_2025_2465178 crossref_primary_10_1007_s11302_020_09693_3 crossref_primary_10_5500_wjt_v13_i4_129 crossref_primary_10_1016_j_biosx_2025_100587 crossref_primary_10_1016_j_pharma_2022_09_006 crossref_primary_10_1016_j_pvr_2019_100185 crossref_primary_10_3389_fimmu_2023_1117545 crossref_primary_10_1002_jmv_28583 crossref_primary_10_1055_s_0041_1739314 crossref_primary_10_1111_sji_12850 crossref_primary_10_3390_molecules27175607 crossref_primary_10_3390_cancers14122968 crossref_primary_10_1016_j_jid_2019_03_1162 crossref_primary_10_1016_S2214_109X_23_00305_4 crossref_primary_10_33483_jfpau_1364203 crossref_primary_10_1089_nat_2020_0869 crossref_primary_10_1186_s13027_020_00281_z crossref_primary_10_1097_PAP_0000000000000466 crossref_primary_10_1371_journal_pone_0294956 crossref_primary_10_3389_fimmu_2024_1445711 crossref_primary_10_1016_j_coviro_2017_07_015 crossref_primary_10_1016_j_coviro_2017_07_014 crossref_primary_10_1128_spectrum_03622_22 crossref_primary_10_1016_j_oraloncology_2022_106245 crossref_primary_10_3390_vaccines11081354 crossref_primary_10_17517_ksutfd_1166590 crossref_primary_10_3390_cancers13225748 crossref_primary_10_1016_j_ctrv_2019_07_001 crossref_primary_10_1016_j_ebiom_2024_105155 crossref_primary_10_3389_fcimb_2020_596166 crossref_primary_10_1186_s12885_018_4198_8 crossref_primary_10_1128_mSphere_00828_19 crossref_primary_10_2174_1381612826666200212115840 crossref_primary_10_1371_journal_ppat_1008524 crossref_primary_10_1002_ijc_34953 crossref_primary_10_1128_spectrum_01836_23 crossref_primary_10_36401_JIPO_20_17 crossref_primary_10_54235_27382737_2023_v3_2_36 crossref_primary_10_1093_jnci_djaa066 crossref_primary_10_1111_aogs_14121 crossref_primary_10_1002_cam4_5431 crossref_primary_10_1038_s41467_022_28724_8 crossref_primary_10_1111_andr_12948 crossref_primary_10_1158_1055_9965_EPI_17_1051 crossref_primary_10_3390_v13050855 crossref_primary_10_1155_2019_3257939 crossref_primary_10_1186_s12885_019_5311_3 crossref_primary_10_1186_s12916_025_03975_6 crossref_primary_10_1002_cam4_4340 crossref_primary_10_1016_S2352_3018_21_00108_9 crossref_primary_10_1093_infdis_jix116 crossref_primary_10_1016_j_jasc_2023_06_001 crossref_primary_10_1590_1414_431x2023e12720 crossref_primary_10_55905_cuadv16n9_032 crossref_primary_10_1002_jmv_29451 crossref_primary_10_1016_S1773_035X_24_00048_0 crossref_primary_10_1158_0008_5472_CAN_22_3030 crossref_primary_10_1016_j_ypmed_2024_107927 crossref_primary_10_3390_v14081797 crossref_primary_10_3390_vaccines12040411 crossref_primary_10_5937_pramed2002013m crossref_primary_10_1016_j_vaccine_2022_09_070 crossref_primary_10_3390_vaccines11101626 crossref_primary_10_5468_ogs_24236 crossref_primary_10_1136_bmjopen_2022_063622 crossref_primary_10_1002_cncy_22018 crossref_primary_10_15446_abc_v23n1_63487 crossref_primary_10_1002_ijc_33879 crossref_primary_10_1038_s41579_018_0064_6 crossref_primary_10_1002_dc_25361 crossref_primary_10_1186_s13000_019_0808_2 crossref_primary_10_1038_s41598_022_09980_6 crossref_primary_10_3390_v17030367 crossref_primary_10_1371_journal_pone_0278117 crossref_primary_10_1002_cncy_22267 crossref_primary_10_1038_s41467_023_37377_0 crossref_primary_10_3389_fcell_2020_00474 crossref_primary_10_1158_0008_5472_CAN_20_1996 crossref_primary_10_3390_v14050950 crossref_primary_10_1016_j_hoc_2024_03_005 crossref_primary_10_1002_cncr_34485 crossref_primary_10_3389_fcimb_2022_1036869 crossref_primary_10_1007_s10989_021_10285_x crossref_primary_10_4014_jmb_2408_08041 crossref_primary_10_1016_j_jpp_2021_02_003 crossref_primary_10_1186_s12905_020_01035_0 crossref_primary_10_1002_ijc_32315 crossref_primary_10_1093_infdis_jiz324 crossref_primary_10_1016_S1470_2045_21_00058_9 crossref_primary_10_1093_infdis_jiy354 crossref_primary_10_1186_s12885_018_4438_y crossref_primary_10_1002_cncy_22695 crossref_primary_10_1002_jmv_29236 crossref_primary_10_1016_j_canep_2023_102435 crossref_primary_10_1158_0008_5472_CAN_17_0642 crossref_primary_10_3390_microorganisms11112769 crossref_primary_10_1016_j_vaccine_2018_04_061 crossref_primary_10_4103_iju_iju_398_22 crossref_primary_10_3389_fonc_2024_1407008 crossref_primary_10_1093_biomet_asaa014 crossref_primary_10_1002_jmv_29473 crossref_primary_10_1016_j_heliyon_2024_e31376 crossref_primary_10_1002_ijc_31119 crossref_primary_10_1016_j_vacune_2023_10_001 crossref_primary_10_1016_j_semradonc_2021_02_006 crossref_primary_10_1002_ijc_32565 crossref_primary_10_1080_21645515_2021_2024065 crossref_primary_10_3389_fcimb_2021_649815 crossref_primary_10_2147_RMHP_S296914 crossref_primary_10_1007_s10900_022_01089_1 crossref_primary_10_1080_08870446_2019_1584673 crossref_primary_10_1002_cam4_3201 crossref_primary_10_15789_2220_7619_TPO_17690 crossref_primary_10_1590_0001_3765202520240824 crossref_primary_10_32604_Oncologie_2021_016002 crossref_primary_10_3390_ijms24033055 crossref_primary_10_1089_jwh_2023_0462 crossref_primary_10_1016_j_tim_2017_07_007 crossref_primary_10_1002_jmv_29480 crossref_primary_10_3390_molecules29050922 crossref_primary_10_3390_v10020080 crossref_primary_10_3390_ijms20092188 crossref_primary_10_1136_ijgc_2021_003014 crossref_primary_10_1186_s42826_023_00166_3 crossref_primary_10_1111_cyt_12943 crossref_primary_10_1016_j_jcv_2021_105014 crossref_primary_10_3389_fmed_2021_700792 crossref_primary_10_1111_jcmm_13595 crossref_primary_10_3389_fcimb_2023_1138232 crossref_primary_10_3390_cancers15061709 crossref_primary_10_3233_CBM_190055 crossref_primary_10_1007_s00011_022_01560_8 crossref_primary_10_1093_infdis_jiy249 crossref_primary_10_1111_1471_0528_15996 crossref_primary_10_1093_nar_gkac213 crossref_primary_10_1002_puh2_126 crossref_primary_10_1159_000497617 crossref_primary_10_1111_tid_14019 crossref_primary_10_2217_fon_2020_0928 crossref_primary_10_1007_s10900_023_01206_8 crossref_primary_10_1016_j_ebiom_2020_103190 crossref_primary_10_1016_j_soncn_2022_151284 crossref_primary_10_1016_j_ijmedinf_2021_104675 crossref_primary_10_1093_infdis_jix299 crossref_primary_10_3390_cancers10070213 crossref_primary_10_3802_jgo_2024_35_e72 crossref_primary_10_1016_j_archoralbio_2017_08_011 crossref_primary_10_2174_0118715265257105231025112708 crossref_primary_10_1186_s13027_025_00643_5 crossref_primary_10_1055_s_0039_1698772 crossref_primary_10_1371_journal_pone_0232474 crossref_primary_10_18632_oncotarget_18328 crossref_primary_10_3233_BD_201032 crossref_primary_10_3322_caac_21628 crossref_primary_10_3390_cells10113104 crossref_primary_10_1002_ijc_31027 crossref_primary_10_1016_j_omton_2024_200892 crossref_primary_10_1097_OLQ_0000000000001718 crossref_primary_10_1099_jgv_0_001213 crossref_primary_10_1371_journal_pone_0257915 crossref_primary_10_1097_CEJ_0000000000000770 crossref_primary_10_1186_s13027_023_00536_5 crossref_primary_10_1158_2326_6066_CIR_21_0119 crossref_primary_10_3389_fmicb_2020_00827 crossref_primary_10_1016_j_eimc_2019_01_010 crossref_primary_10_1038_s41467_018_05733_0 crossref_primary_10_1093_nar_gkad1099 crossref_primary_10_1002_pmic_201700390 crossref_primary_10_1016_j_nano_2021_102429 crossref_primary_10_1097_PAS_0000000000002096 crossref_primary_10_1109_JBHI_2021_3094311 crossref_primary_10_3390_vaccines11071246 crossref_primary_10_1093_nar_gkx606 crossref_primary_10_1016_S2468_2667_17_30242_6 crossref_primary_10_1186_s12859_019_2918_y crossref_primary_10_1038_s41598_021_96038_8 crossref_primary_10_3390_nu15173825 crossref_primary_10_1016_S1473_3099_17_30126_3 crossref_primary_10_1136_jitc_2022_004790 crossref_primary_10_7326_M21_4372 crossref_primary_10_20960_revcancer_00092 crossref_primary_10_3390_pathogens13070564 crossref_primary_10_1136_ijgc_2022_004160 crossref_primary_10_3390_v13010115 crossref_primary_10_1093_jnci_djaa106 crossref_primary_10_3390_v14071361 crossref_primary_10_1080_14737159_2017_1293525 crossref_primary_10_1016_j_vaccine_2023_08_047 crossref_primary_10_3389_fcell_2019_00139 crossref_primary_10_1002_wsbm_1539 crossref_primary_10_3389_fimmu_2023_1051431 crossref_primary_10_1002_dc_24683 crossref_primary_10_1016_j_oraloncology_2024_107169 crossref_primary_10_3390_cancers12051060 crossref_primary_10_1002_ijc_32255 crossref_primary_10_3390_v17030417 crossref_primary_10_3892_or_2021_8196 crossref_primary_10_1371_journal_pone_0300729 crossref_primary_10_3389_fmicb_2019_02093 crossref_primary_10_1002_cpmc_129 crossref_primary_10_1371_journal_pone_0267617 crossref_primary_10_5937_serbjph2203279D crossref_primary_10_1089_whr_2022_0024 crossref_primary_10_1111_tan_14429 crossref_primary_10_1016_j_idnow_2023_104830 crossref_primary_10_1016_j_cell_2017_08_001 crossref_primary_10_1146_annurev_cancerbio_070120_090423 crossref_primary_10_1038_s41525_021_00264_y crossref_primary_10_1182_blood_2020006675 crossref_primary_10_1007_s00428_021_03080_y crossref_primary_10_1186_s12935_019_0935_6 crossref_primary_10_1002_jmv_29500 crossref_primary_10_1158_1535_7163_MCT_19_0375 crossref_primary_10_1016_j_ajt_2024_03_005 crossref_primary_10_1016_j_coviro_2019_06_006 crossref_primary_10_1097_LGT_0000000000000300 crossref_primary_10_1186_s13027_019_0250_9 crossref_primary_10_14777_uti_2448030015 crossref_primary_10_3390_biomedicines11051444 crossref_primary_10_1002_ijc_33233 crossref_primary_10_1016_j_lpmfor_2024_01_011 crossref_primary_10_1093_cid_ciaa238 crossref_primary_10_1017_S0950268821001904 crossref_primary_10_1056_NEJMcp2108502 crossref_primary_10_3390_ijms20010198 crossref_primary_10_1002_advs_202101672 crossref_primary_10_3390_jcm11144225 crossref_primary_10_1016_j_virol_2018_01_002 crossref_primary_10_54022_shsv4n3_007 crossref_primary_10_3390_jcm14061912 crossref_primary_10_4111_icu_20220318 crossref_primary_10_1002_ijc_33365 crossref_primary_10_1016_j_diagmicrobio_2023_116160 crossref_primary_10_1002_jmv_29875 crossref_primary_10_4274_eamr_galenos_2021_62634 crossref_primary_10_1039_D3SC02782A crossref_primary_10_18273_revmed_v37n2_2024002 crossref_primary_10_1159_000508780 crossref_primary_10_1186_s12905_021_01320_6 crossref_primary_10_3390_jcm11041101 crossref_primary_10_1016_j_ad_2022_05_020 crossref_primary_10_3390_microbiolres12030038 crossref_primary_10_1016_j_heliyon_2024_e39148 crossref_primary_10_1093_aje_kwab254 crossref_primary_10_1360_TB_2024_0880 crossref_primary_10_3390_ijerph19159580 crossref_primary_10_1038_s41568_023_00602_5 crossref_primary_10_1186_s12986_021_00615_7 crossref_primary_10_1016_j_vaccine_2024_01_043 crossref_primary_10_1128_JVI_01943_20 crossref_primary_10_1016_j_virol_2019_03_008 crossref_primary_10_4111_icu_20240274 crossref_primary_10_3390_v13020321 crossref_primary_10_1038_s41598_022_06731_5 crossref_primary_10_3390_v15091954 crossref_primary_10_1016_j_ijrobp_2022_04_037 crossref_primary_10_1002_ijc_35312 crossref_primary_10_1002_jmv_29524 crossref_primary_10_1016_j_microc_2025_112991 crossref_primary_10_1016_S1473_3099_20_30873_2 crossref_primary_10_1186_s12889_019_7846_2 crossref_primary_10_1186_s13148_020_00853_1 crossref_primary_10_1111_aji_13930 crossref_primary_10_1590_1414_431x20177098 crossref_primary_10_1515_cclm_2023_0440 crossref_primary_10_3390_v16091357 crossref_primary_10_1016_j_eururo_2022_03_001 crossref_primary_10_1128_mbio_00729_24 crossref_primary_10_2174_1381612826666200114100553 crossref_primary_10_3389_fpubh_2018_00077 crossref_primary_10_1016_j_eimce_2019_01_003 crossref_primary_10_1128_JCM_00492_17 crossref_primary_10_3390_cancers14112607 crossref_primary_10_1007_s00038_019_01261_w crossref_primary_10_1515_hsz_2017_0113 crossref_primary_10_1371_journal_pgen_1007179 crossref_primary_10_1093_jnci_djy225 crossref_primary_10_1016_j_semcancer_2022_02_014 crossref_primary_10_1007_s11010_025_05236_9 crossref_primary_10_1002_dc_25457 crossref_primary_10_1016_j_intimp_2019_01_024 crossref_primary_10_1007_s10654_018_0365_0 crossref_primary_10_3390_cancers17020308 crossref_primary_10_3390_diagnostics14050473 crossref_primary_10_1016_j_ypmed_2020_106076 crossref_primary_10_1186_s13059_021_02307_0 crossref_primary_10_2139_ssrn_4046139 crossref_primary_10_54033_cadpedv21n8_284 crossref_primary_10_7759_cureus_58427 crossref_primary_10_3390_nu12051384 crossref_primary_10_3389_fonc_2021_626187 crossref_primary_10_3390_ijms242316808 crossref_primary_10_1111_his_14019 crossref_primary_10_51523_2708_6011_2020_17_4_3 crossref_primary_10_1016_j_ygyno_2019_02_024 crossref_primary_10_1002_jmv_70191 crossref_primary_10_3390_v16121965 crossref_primary_10_1128_JCM_01794_18 crossref_primary_10_3390_ijms252312991 crossref_primary_10_3390_v9120370 crossref_primary_10_1016_j_nanoso_2020_100457 crossref_primary_10_2196_games_8540 crossref_primary_10_1097_OLQ_0000000000001830 crossref_primary_10_1007_s11033_023_08939_8 crossref_primary_10_1098_rstb_2018_0287 crossref_primary_10_1016_j_tvr_2024_200287 crossref_primary_10_1017_S0950268817002448 crossref_primary_10_1158_1078_0432_CCR_24_0385 crossref_primary_10_3389_fmicb_2023_1292230 crossref_primary_10_2174_1574884716666210325095022 crossref_primary_10_1056_NEJMsr2030640 crossref_primary_10_1136_bmjopen_2017_020343 crossref_primary_10_1016_S2468_1253_20_30304_6 crossref_primary_10_1177_10732748221103331 crossref_primary_10_1016_j_oraloncology_2020_105040 crossref_primary_10_1186_s12906_023_03960_7 crossref_primary_10_3390_cancers14174151 crossref_primary_10_1016_j_gofs_2021_10_012 crossref_primary_10_1371_journal_pone_0225496 crossref_primary_10_1158_1055_9965_EPI_20_0749 crossref_primary_10_1007_s12094_024_03524_2 crossref_primary_10_1016_j_amjms_2020_11_031 crossref_primary_10_1186_s13027_024_00585_4 crossref_primary_10_1016_j_ypmed_2021_106596 crossref_primary_10_1093_jnci_djz074 crossref_primary_10_1186_s12905_021_01356_8 crossref_primary_10_1042_BSR20203488 crossref_primary_10_1038_s41598_018_33865_2 crossref_primary_10_7554_eLife_85735 crossref_primary_10_3389_fimmu_2021_645299 crossref_primary_10_1007_s00439_020_02183_x crossref_primary_10_1016_j_talanta_2019_07_006 crossref_primary_10_1097_PAS_0000000000000984 crossref_primary_10_3390_cancers15082390 crossref_primary_10_3390_microorganisms9050891 crossref_primary_10_1111_ajt_15292 crossref_primary_10_3390_cancers14246090 crossref_primary_10_1016_j_jviromet_2018_10_007 crossref_primary_10_1016_j_gore_2024_101669 crossref_primary_10_1038_s41467_024_45807_w crossref_primary_10_1186_s12905_021_01310_8 crossref_primary_10_1016_j_clinsp_2022_100080 crossref_primary_10_1038_s41420_021_00689_5 crossref_primary_10_1177_11769351221084808 crossref_primary_10_3390_ijms23095050 crossref_primary_10_1016_j_coviro_2021_09_002 crossref_primary_10_1186_s12951_024_02831_8 crossref_primary_10_3390_ijms20163902 crossref_primary_10_1002_cncy_22704 crossref_primary_10_1016_j_ajog_2017_05_068 crossref_primary_10_1002_osi2_1205 crossref_primary_10_1002_jso_27633 crossref_primary_10_3389_fimmu_2018_00830 crossref_primary_10_54817_IC_v64n2a09 crossref_primary_10_1016_j_ypmed_2021_106438 crossref_primary_10_1016_j_ypmed_2021_106439 crossref_primary_10_1016_j_pmedr_2024_102955 crossref_primary_10_3390_pharmaceutics16070864 crossref_primary_10_1128_spectrum_00779_22 crossref_primary_10_7717_peerj_12578 crossref_primary_10_1016_j_tranon_2021_101267 crossref_primary_10_1038_s41467_021_27628_3 crossref_primary_10_1016_j_coviro_2021_09_014 crossref_primary_10_3390_cancers13164038 crossref_primary_10_2217_imt_2019_0196 crossref_primary_10_3389_fonc_2022_761219 crossref_primary_10_1016_j_amepre_2021_06_026 crossref_primary_10_1016_j_coviro_2021_09_010 crossref_primary_10_5858_arpa_2023_0193_OA crossref_primary_10_3389_fimmu_2018_01914 crossref_primary_10_1016_j_jmoldx_2019_04_010 crossref_primary_10_3390_ijms25052798 crossref_primary_10_3390_pathogens13080653 crossref_primary_10_1186_s12885_024_13079_8 crossref_primary_10_1158_1055_9965_EPI_20_1628 crossref_primary_10_3166_cer_2019_0064 crossref_primary_10_3390_cancers14133038 crossref_primary_10_1155_2018_6583852 crossref_primary_10_3390_v13061173 crossref_primary_10_3390_jcm13123597 crossref_primary_10_2174_1389557523666230213140641 crossref_primary_10_26416_Inf_54_2_2018_1830 crossref_primary_10_1038_s41585_025_00994_z crossref_primary_10_1038_s41467_024_51713_y crossref_primary_10_1186_s13104_020_05422_6 crossref_primary_10_3389_fgene_2020_00819 crossref_primary_10_1099_jgv_0_001019 crossref_primary_10_3390_v16030416 crossref_primary_10_1155_2022_1372926 crossref_primary_10_1136_ijgc_2020_001587 crossref_primary_10_4103_ijot_ijot_60_23 crossref_primary_10_1007_s40136_021_00386_y crossref_primary_10_1186_s12985_023_01959_7 crossref_primary_10_31067_acusaglik_1137841 crossref_primary_10_3390_vaccines11010102 crossref_primary_10_1186_s13027_021_00395_y crossref_primary_10_1111_1471_0528_17597 crossref_primary_10_1093_jnci_djy044 crossref_primary_10_1371_journal_ppat_1011464 crossref_primary_10_1016_j_euf_2022_04_012 crossref_primary_10_3389_fimmu_2024_1335302 crossref_primary_10_1007_s40944_024_00822_z crossref_primary_10_1371_journal_ppat_1009028 crossref_primary_10_1002_jmv_27978 crossref_primary_10_1016_j_bioelechem_2024_108795 crossref_primary_10_1038_s41572_021_00246_5 crossref_primary_10_1002_ijc_31918 crossref_primary_10_1002_ctd2_57 crossref_primary_10_1016_S1773_035X_21_00070_8 crossref_primary_10_1158_1940_6207_CAPR_21_0110 crossref_primary_10_3389_fonc_2022_891511 crossref_primary_10_3390_v15122411 crossref_primary_10_3389_fonc_2018_00077 crossref_primary_10_1128_jvi_00951_24 crossref_primary_10_3390_biology13030184 crossref_primary_10_1158_1055_9965_EPI_22_0548 crossref_primary_10_1097_GME_0000000000002222 crossref_primary_10_3390_cancers13164083 crossref_primary_10_34172_bi_2020_30 crossref_primary_10_1002_ijgo_14442 crossref_primary_10_1002_jmv_28834 crossref_primary_10_1007_s12088_024_01369_5 crossref_primary_10_1099_jgv_0_001236 crossref_primary_10_1186_s12964_023_01365_0 crossref_primary_10_51847_fe28C95Ygw crossref_primary_10_1007_s11262_022_01889_6 crossref_primary_10_1186_s12905_024_03254_1 crossref_primary_10_1055_s_0038_1657754 crossref_primary_10_1080_14737167_2025_2451732 crossref_primary_10_1158_1535_7163_MCT_19_0625 crossref_primary_10_1128_JVI_01509_20 crossref_primary_10_1016_j_genrep_2020_100958 crossref_primary_10_1016_j_gene_2021_146016 crossref_primary_10_1186_s12985_022_01894_z crossref_primary_10_2478_fon_2024_0047 crossref_primary_10_1016_j_eclinm_2020_100293 crossref_primary_10_3390_cancers15020509 crossref_primary_10_1016_S1470_2045_22_00543_5 crossref_primary_10_2147_RMHP_S278809 crossref_primary_10_1007_s10989_019_09985_2 crossref_primary_10_1097_MD_0000000000037068 crossref_primary_10_3389_fonc_2021_753102 crossref_primary_10_3390_v13101892 crossref_primary_10_1097_LGT_0000000000000743 crossref_primary_10_1089_whr_2023_0153 crossref_primary_10_1097_LGT_0000000000000742 crossref_primary_10_2139_ssrn_3925469 crossref_primary_10_3389_fcimb_2022_917009 |
| Cites_doi | 10.1158/1940-6207.CAPR-09-0031 10.1016/j.vaccine.2012.06.083 10.1056/NEJMoa1010971 10.1001/jama.2012.101 10.1128/JCM.02116-14 10.1371/journal.pone.0074797 10.1016/j.oraloncology.2012.06.019 10.4161/hv.7.12.18322 10.1056/NEJMoa1405044 10.1002/ijc.28228 10.1097/QAD.0000000000000160 10.2741/2739 10.1002/ijc.30032 10.1084/jem.20151531 10.1128/JVI.07069-11 10.1128/JVI.77.15.8378-8385.2003 10.1158/0008-5472.CAN-06-1812 10.1016/j.jviromet.2007.10.005 10.6004/jnccn.2015.0102 10.1016/j.vaccine.2010.12.085 10.1038/bjc.2013.22 10.1200/JCO.2013.50.3870 10.1016/j.tem.2010.03.005 10.1002/ijc.27485 10.3322/caac.21259 10.1002/ijc.21953 10.1200/JCO.2015.62.3157 10.1016/S0140-6736(06)69479-8 10.1016/j.vaccine.2012.06.095 10.1016/j.vaccine.2012.04.106 10.1200/JCO.2014.55.9948 10.1001/jama.2013.1625 10.1016/j.virol.2011.12.018 10.1086/657321 10.1016/S0140-6736(07)61684-5 10.1038/modpathol.2015.52 10.1016/S1470-2045(11)70287-X 10.1016/j.vaccine.2012.04.108 10.1200/JCO.2007.10.8324 10.1038/nrclinonc.2015.146 10.1158/1055-9965.EPI-12-0483 10.1016/S1470-2045(11)70286-8 10.1093/jnci/dju153 10.1186/s12879-014-0578-0 10.1016/j.surge.2016.03.006 10.1093/jnci/djt235 10.1099/0022-1317-83-9-2299 10.1038/bjc.2011.185 10.1093/jnci/djn011 10.1158/1078-0432.CCR-14-1099 10.1371/journal.pone.0048954 10.1093/jnci/djq342 10.1128/JVI.02901-14 10.1093/jnci/88.19.1361 10.1016/j.jcv.2004.12.006 10.1097/QAD.0b013e328333ab8e 10.1016/j.virol.2013.04.013 10.1097/PGP.0b013e31826916c7 10.1016/j.virol.2013.04.035 10.1200/JGO.2016.003947 10.1158/0008-5472.CAN-07-2754 10.1016/j.vaccine.2015.06.088 10.1016/j.oraloncology.2013.11.004 10.3390/v7072785 10.1093/infdis/jiu330 10.1016/S1470-2045(08)70103-7 10.1016/j.oraloncology.2013.09.008 10.1093/jnci/djw100 10.1073/pnas.1509322112 10.1093/emph/eov003 10.1016/j.virol.2013.05.012 10.1016/S0140-6736(13)60022-7 10.1093/jnci/djs135 10.1038/jid.2008.156 10.1016/j.ygyno.2013.06.005 10.1016/S2214-109X(16)30143-7 10.1093/jnci/djv403 10.1128/JVI.80.9.4431-4439.2006 10.1016/S1470-2045(09)70096-8 10.1086/604729 10.1093/jnci/dju423 10.3390/v7072802 10.1016/j.oraloncology.2013.09.003 10.1002/ijc.21493 10.1111/jop.12123 10.1038/nri3819 10.1042/CS20050369 10.1093/jnci/djp534 10.1158/1940-6207.CAPR-13-0091 10.1016/j.virol.2013.04.026 10.1097/01.AOG.0000220505.18525.85 10.1016/j.ygyno.2014.12.022 10.1056/NEJMoa1309748 10.1016/S1473-3099(14)71073-4 10.3390/v7052485 10.1093/cid/ciw354 10.1128/JVI.02137-15 10.1016/j.jcv.2015.11.015 10.3390/vaccines3020408 10.1158/1055-9965.EPI-08-0151 10.1073/pnas.0409883102 10.1016/S1470-2045(08)70110-4 10.1158/0008-5472.CAN-13-0587 10.1002/ijc.28886 10.1097/LGT.0000000000000170 10.1086/516784 10.1016/j.tim.2010.12.006 10.2741/1971 10.1093/infdis/jit577 10.1016/j.coviro.2013.06.003 10.1073/pnas.1202684109 10.1111/j.1365-2249.2007.03468.x 10.1016/j.ejca.2013.04.024 10.1016/j.vaccine.2013.10.003 10.1002/ijc.28963 10.1200/JCO.2014.56.8733 10.1002/cncy.21596 10.1002/ijc.24116 10.1200/JCO.2014.55.1937 10.1016/j.ajpath.2013.10.013 10.1128/JVI.06450-11 10.1002/cncy.21571 10.1136/bmj.g130 10.1097/LGT.0b013e31825934c7 10.1002/path.4435 10.1002/cncy.21622 10.1016/j.jcv.2014.02.002 10.1016/j.jcv.2013.12.014 10.1111/j.1471-0528.2011.02970.x 10.1016/S0140-6736(07)61416-0 10.1159/000214919 10.1097/AOG.0b013e31818f5008 10.1016/S1470-2045(15)00047-9 10.1097/LGT.0b013e31806dba20 10.1038/nature05574 10.6004/jnccn.2014.0142 10.1128/CMR.05028-11 10.1002/em.20478 10.1038/bjc.2014.362 10.1093/jnci/djv185 10.1158/0008-5472.CAN-04-0009 10.1128/JVI.02589-13 10.1002/cncr.29921 10.1097/LGT.0b013e31819308d4 10.1016/S1470-2045(12)70529-6 10.1016/S0140-6736(15)00239-1 10.1016/j.ijgo.2015.07.038 10.1016/j.ajog.2004.02.065 10.1136/jclinpath-2014-202616 10.1038/sj.onc.1209950 10.1093/jnci/djs425 10.1016/j.cellimm.2015.01.018 10.1016/j.ijgo.2015.07.024 10.1097/QAD.0000000000000808 10.1097/PAS.0000000000000498 10.1371/journal.ppat.1000318 10.1016/j.vaccine.2006.06.005 10.1056/NEJMoa0909537 10.1158/1055-9965.EPI-11-0664 10.1016/j.vaccine.2004.09.035 10.1002/ijc.26250 10.1002/ijc.29877 10.1016/j.eururo.2015.12.007 10.1097/AOG.0b013e31816baed1 10.1016/S0140-6736(13)62218-7 10.2165/11205980-000000000-00000 10.1002/ijc.20257 10.4049/jimmunol.1002756 10.4161/hv.7.12.18282 10.1016/j.pvr.2015.06.007 10.1016/j.virol.2013.04.033 10.1016/j.virol.2013.04.034 10.1186/1750-9378-4-8 10.1093/jnci/djn044 10.1016/j.ygyno.2014.02.001 10.1002/ijc.29438 10.1056/NEJMoa0912217 10.1093/jnci/djv257 10.1126/science.1206923 10.1093/infdis/jiv498 10.1093/jnci/djq436 10.1016/S0168-1702(02)00196-X 10.1200/JCO.2012.47.2738 10.1038/nrclinonc.2013.84 10.1111/j.1471-0528.2008.01936.x 10.1146/annurev.pathol.4.110807.092158 10.1158/1055-9965.EPI-12-1406 10.1071/SH15089 10.1016/S0140-6736(04)16674-9 10.3201/eid2201.150791 10.1128/JVI.02726-07 10.1128/JVI.02383-14 10.1136/bmj.h3084 10.1093/infdis/jir286 10.1371/journal.ppat.1002833 10.1016/j.oraloncology.2015.08.006 10.1038/bjc.2013.639 10.1158/0008-5472.CAN-12-2606 10.1016/j.virol.2011.03.019 10.1002/ijc.30456 10.1016/S1473-3099(16)30116-5 |
| ContentType | Journal Article |
| Copyright | Macmillan Publishers Limited 2016 Macmillan Publishers Limited 2016. |
| Copyright_xml | – notice: Macmillan Publishers Limited 2016 – notice: Macmillan Publishers Limited 2016. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M2P M7P PHGZM PHGZT PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1038/nrdp.2016.86 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Science Database Biological Science Database (ProQuest) ProQuest Central Premium ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2056-676X |
| ExternalDocumentID | 27905473 10_1038_nrdp_2016_86 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_PC_13050 – fundername: Medical Research Council grantid: MC_U117584278 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | 0R~ 53G 7X7 88I 8FI 8FJ AAEEF AARCD AAWYQ AAZLF ABJNI ABLJU ABUWG ACGFS ACMJI ADBBV AFKRA AFSHS AGAYW AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ARMCB AXYYD AZQEC BENPR BKKNO CCPQU DWQXO EBS EJD FQGFK FSGXE FYUFA FZEXT GNUQQ HCIFZ HMCUK M2P NNMJJ NXXTH R9- RNR RNT SHXYY SIXXV SNYQT SOJ TAOOD TBHMF TDRGL TSG UKHRP AAYXX ABFSG ACMFV ACSTC AEZWR AFANA AFHIU AHWEU AIXLP ATHPR BBNVY BHPHI CITATION M7P PHGZM PHGZT CGR CUY CVF ECM EIF NPM PQGLB 3V. 7XB 8FE 8FH 8FK K9. LK8 PKEHL PQEST PQQKQ PQUKI PRINS PUEGO Q9U 7X8 |
| ID | FETCH-LOGICAL-c423t-f5db89345e0ef90e6e66cb18d97df13b1d621b36f72b69c46f97b30e43beb42e3 |
| IEDL.DBID | 7X7 |
| ISSN | 2056-676X |
| IngestDate | Thu Sep 04 14:59:03 EDT 2025 Sat Aug 23 14:49:44 EDT 2025 Mon Jul 21 06:01:42 EDT 2025 Tue Jul 01 02:52:20 EDT 2025 Thu Apr 24 23:08:08 EDT 2025 Fri Feb 21 02:37:57 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c423t-f5db89345e0ef90e6e66cb18d97df13b1d621b36f72b69c46f97b30e43beb42e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 27905473 |
| PQID | 2711097004 |
| PQPubID | 2069613 |
| ParticipantIDs | proquest_miscellaneous_1845252572 proquest_journals_2711097004 pubmed_primary_27905473 crossref_primary_10_1038_nrdp_2016_86 crossref_citationtrail_10_1038_nrdp_2016_86 springer_journals_10_1038_nrdp_2016_86 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-12-01 |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature reviews. Disease primers |
| PublicationTitleAbbrev | Nat Rev Dis Primers |
| PublicationTitleAlternate | Nat Rev Dis Primers |
| PublicationYear | 2016 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Cuzick (CR128) 2013; 108 Doorbar (CR54) 2006; 110 Tummers, Burg (CR82) 2015; 7 Pfister (CR174) 2014; 12 Doorbar (CR61) 2013; 3 Wira, Rodriguez-Garcia, Patel (CR97) 2015; 15 Castellsagué (CR111) 2011; 105 Reich, Pickel, Regauer (CR210) 2008; 12 CR163 Benson, Li, Eisele, Fakhry (CR181) 2014; 50 Ward (CR184) 2014; 110 Schiffman, Rodríguez (CR44) 2008; 9 Peto, Gilham, Fletcher, Matthews (CR43) 2004; 364 Mirabello (CR141) 2012; 104 Luhn (CR144) 2013; 130 Kovats (CR98) 2015; 294 Chow (CR162) 2016 Schiffman, Wentzensen (CR157) 2016; 20 Cremer (CR203) 2016; 2 Kelly, Walker, Kitchener, Moss (CR150) 2012; 119 Doorbar (CR52) 2012; 30 Einstein (CR101) 2011; 7 CR169 Plummer, Peto, Franceschi (CR45) 2012; 130 Vaccarella (CR10) 2014; 111 Elfström (CR120) 2014; 348 Petry (CR152) 2016; 138 Palefsky (CR156) 2015; 123 Egawa, Egawa, Griffin, Doorbar (CR62) 2015; 7 Joura (CR103) 2015; 372 de Martel (CR14) 2015; 29 Maglennon, McIntosh, Doorbar (CR92) 2011; 414 Herfs, Hubert, Moutschen, Delvenne (CR211) 2011; 19 Sundström (CR20) 2015; 107 Ronco (CR27) 2014; 383 Klingelhutz, Roman (CR71) 2012; 424 Matthews (CR86) 2003; 77 CR134 Egawa (CR66) 2012; 86 Romanowski (CR110) 2011; 7 Wentzensen, Schiffman, Palmer, Arbyn (CR129) 2016; 76 Badoual (CR185) 2013; 73 Monk, Tewari, Koh (CR172) 2007; 25 (CR36) 2006; 118 Burgers (CR78) 2007; 26 Denny, Kuhn, Hu, Tsai, Wright (CR201) 2010; 102 Lehtinen, Dillner (CR32) 2013; 10 Campos (CR190) 2015; 137 Ronco (CR127) 2012; 36 Bernard (CR55) 2013; 445 Fakhry (CR176) 2014; 32 Martens, Arends, Van der Linden, De Boer, Helmerhorst (CR209) 2004; 24 Rodríguez (CR3) 2008; 100 Mirabello (CR195) 2016; 108 Stanley, Pinto, Trimble (CR99) 2012; 30 Stanley (CR80) 2012; 25 Kimple (CR182) 2013; 73 Trimble (CR164) 2015; 386 Dalla Pria (CR154) 2014; 28 Houlihan, O'Neill (CR171) 2016; 14 (CR37) 2006; 119 Dobson (CR109) 2013; 309 Bergeron (CR131) 2015; 107 Vasiljevic, Scibior-Bentkowska, Brentnall, Cuzick, Lorincz (CR140) 2014; 132 Wheeler (CR119) 2012; 13 Burger (CR168) 1996; 88 Gage (CR124) 2014; 106 Gillison (CR35) 2012; 307 Herfs (CR161) 2012; 109 CR126 Giuliano (CR28) 2008; 17 Garland (CR116) 2016; 63 CR122 Roman, Munger (CR72) 2013; 445 Alemany (CR13) 2016; 69 Visser (CR89) 2007; 150 Schiffman, Clifford, Buonaguro (CR193) 2009; 4 Santesso (CR212) 2016; 132 Habiger, Jäger, Walter, Iftner, Stubenrauch (CR83) 2016; 90 van der Burg, de Jong, Welters, Offringa, Melief (CR88) 2002; 89 Huh (CR125) 2015; 136 Fakhry, Andersen, Eisele, Gillison (CR178) 2015; 51 Bouvard (CR192) 2009; 10 Pretorius (CR148) 2004; 191 Markowitz, Sternberg, Dunne, McQuillan, Unger (CR29) 2009; 200 Giannini (CR100) 2006; 24 Kreimer (CR197) 2015; 16 den Boon (CR47) 2015; 112 Trimble (CR90) 2010; 185 Palefsky (CR107) 2011; 365 Wentzensen (CR22) 2014; 209 Lu (CR30) 2012; 21 Safaeian (CR39) 2010; 102 Muñoz (CR112) 2010; 102 van Baars (CR146) 2015; 39 Richardson (CR132) 2015; 123 Fausch, Da Silva, Kast (CR84) 2005; 23 Plummer (CR6) 2016; 4 De Strooper (CR139) 2014; 67 Baussano, Lazzarato, Brisson, Franceschi (CR206) 2016; 22 Rietbergen (CR51) 2014; 43 CR105 Schiller, Castellsagué, Garland (CR114) 2012; 30 Van Doorslaer (CR2) 2013; 445 Heaton, Borg, Dixit (CR81) 2016; 213 Guan (CR5) 2012; 131 Mustafa (CR199) 2016; 132 CR108 Ikenberg (CR135) 2013; 105 Bosch (CR4) 2013; 31 Gravitt (CR207) 2016; 213 Smith (CR40) 2004; 111 Cornall (CR59) 2013; 133 Maglennon, McIntosh, Doorbar (CR93) 2014; 88 Massad, Jeronimo, Katki, Schiffman (CR151) 2009; 13 O'Rorke (CR180) 2012; 48 Tewari (CR166) 2014; 370 Nathan (CR155) 2010; 24 Schwartz (CR56) 2013; 445 Scherpenisse (CR118) 2013; 8 Gargano (CR41) 2012; 21 Bodily, Hennigan, Wrobel, Rodriguez (CR68) 2013; 443 Schiffman (CR138) 2015; 53 Arbyn (CR123) 2012; 30 Moore, Nicholls, Santos, Gough, Stanley (CR91) 2002; 83 Shridhar, Shibata, Chan, Thomas (CR173) 2015; 65 Bruni (CR24) 2010; 202 Lehtinen (CR113) 2012; 13 Hubert (CR95) 2014; 234 Giuliano (CR117) 2015; 1 Tsikouras (CR170) 2016; 21 Ganti (CR73) 2015; 7 Palmer (CR34) 2014; 135 Fokom-Domgue (CR200) 2015; 351 Pfister (CR187) 2015; 13 Castellsagué (CR15) 2016; 108 Ang (CR177) 2010; 363 Canfell (CR189) 2011; 29 de Araujo-Souza (CR23) 2014; 14 Wentzensen, Vinokurova, von Knebel Doeberitz (CR75) 2004; 64 Combes, Franceschi (CR16) 2014; 50 Isaacson Wechsler (CR69) 2012; 86 Kreimer (CR18) 2013; 31 Massad, Jeronimo, Schiffman (CR130) 2008; 111 Pyeon, Pearce, Lank, Ahlquist, Lambert (CR60) 2009; 5 Kovacic (CR194) 2006; 66 Alemany (CR11) 2015; 136 Carozzi (CR136) 2013; 14 Agrawal (CR183) 2011; 333 Vaccarella, Lortet-Tieulent, Plummer, Franceschi, Bray (CR42) 2013; 49 Gage (CR147) 2006; 108 Pai, Westra (CR50) 2009; 4 D'Costa (CR79) 2012; 7 Crosbie, Einstein, Franceschi, Kitchener (CR9) 2013; 382 Doorbar (CR58) 2005; 32 Valdez (CR202) 2016; 138 Darragh (CR196) 2013; 32 Vasiljevic, Scibior-Bentkowska, Brentnall, Cuzick, Lorincz (CR142) 2014; 59 Bornstein (CR153) 2012; 16 Liu, Rashid, Nyitray (CR19) 2016; 13 Vinokurova (CR76) 2008; 68 Zhao (CR145) 2013; 6 Warren (CR77) 2015; 89 De Vuyst, Clifford, Nascimento, Madeleine, Franceschi (CR12) 2009; 124 Vaccarella (CR21) 2011; 204 Buck (CR53) 2008; 82 Bravo, Félez-Sánchez (CR1) 2015; 2015 Holsinger, Ferris (CR186) 2015; 33 Hoffmann, Hirt, Bechtold, Beard, Raj (CR65) 2006; 80 Patel (CR179) 2016; 122 Woo (CR87) 2008; 115 Cladel, Hu, Balogh, Mejia, Christensen (CR63) 2008; 148 McCredie (CR158) 2008; 9 Tewari, Monk (CR165) 2014; 20 Giuliano (CR102) 2011; 364 Castellsagué (CR104) 2015; 33 Drolet (CR115) 2015; 15 Cuzick (CR137) 2014; 60 Giorgi Rossi (CR188) 2016; 124 Castle, Schiffman, Wheeler, Solomon (CR159) 2009; 113 Valencia (CR64) 2008; 128 Spurgeon, Chung, Lambert (CR49) 2014; 184 Bosch (CR198) 2016; 13 Chung, Franceschi, Lambert (CR46) 2010; 21 Schiffman, Castle, Jeronimo, Rodriguez, Wacholder (CR26) 2007; 370 CR8 CR7 Monk, Tewari (CR167) 2014; 32 Wiens, Smith (CR96) 2015; 89 Brotman (CR94) 2014; 210 Fakhry (CR175) 2008; 100 Hanson, Eckert, Bloem, Cernuschi (CR106) 2015; 3 Kjaer (CR121) 2009; 2 Vande Pol, Klingelhutz (CR70) 2013; 445 Griffin (CR160) 2015; 28 (CR38) 2007; 370 Brake, Lambert (CR48) 2005; 102 Zheng, Baker (CR67) 2006; 11 Duensing (CR74) 2009; 50 Schiffman, Wentzensen (CR204) 2013; 22 Wise-Draper, Wells (CR57) 2008; 13 Clayton (CR208) 2007; 446 Chung, Bagheri, D'Souza (CR33) 2014; 50 Garnock-Jones, Giuliano (CR31) 2011; 71 Wellings (CR205) 2006; 368 Sperling (CR85) 2012; 8 Chaturvedi (CR17) 2013; 31 Wentzensen (CR143) 2012; 104 Wentzensen (CR133) 2015; 107 Wentzensen (CR149) 2015; 33 Plummer (CR25) 2007; 195 Burk, Chen, Van Doorslaer (CR191) 2009; 12 LS Massad (BFnrdp201686_CR151) 2009; 13 SC Fausch (BFnrdp201686_CR84) 2005; 23 O Reich (BFnrdp201686_CR210) 2008; 12 K Van Doorslaer (BFnrdp201686_CR2) 2013; 445 H Ikenberg (BFnrdp201686_CR135) 2013; 105 RJ Kimple (BFnrdp201686_CR182) 2013; 73 DG Pfister (BFnrdp201686_CR187) 2015; 13 BFnrdp201686_CR108 M Lehtinen (BFnrdp201686_CR32) 2013; 10 BFnrdp201686_CR105 M Schiffman (BFnrdp201686_CR204) 2013; 22 LE Markowitz (BFnrdp201686_CR29) 2009; 200 S Kovats (BFnrdp201686_CR98) 2015; 294 P Luhn (BFnrdp201686_CR144) 2013; 130 MJ Ward (BFnrdp201686_CR184) 2014; 110 K Wellings (BFnrdp201686_CR205) 2006; 368 M Lehtinen (BFnrdp201686_CR113) 2012; 13 BFnrdp201686_CR134 E Benson (BFnrdp201686_CR181) 2014; 50 EJ Crosbie (BFnrdp201686_CR9) 2013; 382 M Safaeian (BFnrdp201686_CR39) 2010; 102 M Schiffman (BFnrdp201686_CR26) 2007; 370 J Doorbar (BFnrdp201686_CR61) 2013; 3 L Mirabello (BFnrdp201686_CR141) 2012; 104 International Collaboration of Epidemiological Studies of Cervical Cancer (BFnrdp201686_CR38) 2007; 370 PE Castle (BFnrdp201686_CR159) 2009; 113 N Vasiljevic (BFnrdp201686_CR142) 2014; 59 SR Dobson (BFnrdp201686_CR109) 2013; 309 P Giorgi Rossi (BFnrdp201686_CR188) 2016; 124 JS Smith (BFnrdp201686_CR40) 2004; 111 BFnrdp201686_CR126 M Schiffman (BFnrdp201686_CR138) 2015; 53 BFnrdp201686_CR122 J Cuzick (BFnrdp201686_CR137) 2014; 60 E Clayton (BFnrdp201686_CR208) 2007; 446 TM Wise-Draper (BFnrdp201686_CR57) 2008; 13 MA Patel (BFnrdp201686_CR179) 2016; 122 N Wentzensen (BFnrdp201686_CR75) 2004; 64 LA Richardson (BFnrdp201686_CR132) 2015; 123 CL Trimble (BFnrdp201686_CR164) 2015; 386 D Pyeon (BFnrdp201686_CR60) 2009; 5 J Doorbar (BFnrdp201686_CR58) 2005; 32 ZJ D'Costa (BFnrdp201686_CR79) 2012; 7 CB Buck (BFnrdp201686_CR53) 2008; 82 IG Bravo (BFnrdp201686_CR1) 2015; 2015 NM Cladel (BFnrdp201686_CR63) 2008; 148 B Lu (BFnrdp201686_CR30) 2012; 21 JW Gargano (BFnrdp201686_CR41) 2012; 21 CH Chung (BFnrdp201686_CR33) 2014; 50 M Drolet (BFnrdp201686_CR115) 2015; 15 AC Rodríguez (BFnrdp201686_CR3) 2008; 100 X Castellsagué (BFnrdp201686_CR111) 2011; 105 M Arbyn (BFnrdp201686_CR123) 2012; 30 N Wentzensen (BFnrdp201686_CR22) 2014; 209 X Castellsagué (BFnrdp201686_CR104) 2015; 33 P Tsikouras (BFnrdp201686_CR170) 2016; 21 M Nathan (BFnrdp201686_CR155) 2010; 24 C Fakhry (BFnrdp201686_CR175) 2008; 100 CJ Warren (BFnrdp201686_CR77) 2015; 89 M Herfs (BFnrdp201686_CR161) 2012; 109 SB Vande Pol (BFnrdp201686_CR70) 2013; 445 H Griffin (BFnrdp201686_CR160) 2015; 28 NG Campos (BFnrdp201686_CR190) 2015; 137 C Fakhry (BFnrdp201686_CR178) 2015; 51 AM Cornall (BFnrdp201686_CR59) 2013; 133 EPF Chow (BFnrdp201686_CR162) 2016 R Shridhar (BFnrdp201686_CR173) 2015; 65 KM Elfström (BFnrdp201686_CR120) 2014; 348 C Habiger (BFnrdp201686_CR83) 2016; 90 M Plummer (BFnrdp201686_CR45) 2012; 130 MA Stanley (BFnrdp201686_CR80) 2012; 25 JM Bodily (BFnrdp201686_CR68) 2013; 443 J Peto (BFnrdp201686_CR43) 2004; 364 B Tummers (BFnrdp201686_CR82) 2015; 7 N Agrawal (BFnrdp201686_CR183) 2011; 333 L Bruni (BFnrdp201686_CR24) 2010; 202 J Visser (BFnrdp201686_CR89) 2007; 150 JC Gage (BFnrdp201686_CR124) 2014; 106 SH van der Burg (BFnrdp201686_CR88) 2002; 89 P Guan (BFnrdp201686_CR5) 2012; 131 JM Palefsky (BFnrdp201686_CR156) 2015; 123 International Collaboration of Epidemiological Studies of Cervical Cancer (BFnrdp201686_CR36) 2006; 118 RD Burk (BFnrdp201686_CR191) 2009; 12 CR Wira (BFnrdp201686_CR97) 2015; 15 LS Massad (BFnrdp201686_CR130) 2008; 111 J Doorbar (BFnrdp201686_CR54) 2006; 110 ME Spurgeon (BFnrdp201686_CR49) 2014; 184 RA Moore (BFnrdp201686_CR91) 2002; 83 M Schiffman (BFnrdp201686_CR44) 2008; 9 SM Heaton (BFnrdp201686_CR81) 2016; 213 BFnrdp201686_CR169 J Bornstein (BFnrdp201686_CR153) 2012; 16 TM Darragh (BFnrdp201686_CR196) 2013; 32 BFnrdp201686_CR163 FC Holsinger (BFnrdp201686_CR186) 2015; 33 X Castellsagué (BFnrdp201686_CR15) 2016; 108 ME Wiens (BFnrdp201686_CR96) 2015; 89 M Scherpenisse (BFnrdp201686_CR118) 2013; 8 G Ronco (BFnrdp201686_CR127) 2012; 36 DG Pfister (BFnrdp201686_CR174) 2014; 12 JT Schiller (BFnrdp201686_CR114) 2012; 30 M Valdez (BFnrdp201686_CR202) 2016; 138 BJ Monk (BFnrdp201686_CR172) 2007; 25 Z-M Zheng (BFnrdp201686_CR67) 2006; 11 EA Joura (BFnrdp201686_CR103) 2015; 372 M Plummer (BFnrdp201686_CR25) 2007; 195 A Dalla Pria (BFnrdp201686_CR154) 2014; 28 M Schiffman (BFnrdp201686_CR193) 2009; 4 MA O'Rorke (BFnrdp201686_CR180) 2012; 48 C Fakhry (BFnrdp201686_CR176) 2014; 32 AK Chaturvedi (BFnrdp201686_CR17) 2013; 31 JE Martens (BFnrdp201686_CR209) 2004; 24 LMA De Strooper (BFnrdp201686_CR139) 2014; 67 N Egawa (BFnrdp201686_CR62) 2015; 7 WA Burgers (BFnrdp201686_CR78) 2007; 26 BFnrdp201686_CR7 BFnrdp201686_CR8 S Vaccarella (BFnrdp201686_CR42) 2013; 49 RM Brotman (BFnrdp201686_CR94) 2014; 210 JA den Boon (BFnrdp201686_CR47) 2015; 112 J Doorbar (BFnrdp201686_CR52) 2012; 30 M Stanley (BFnrdp201686_CR99) 2012; 30 OA Houlihan (BFnrdp201686_CR171) 2016; 14 R Hoffmann (BFnrdp201686_CR65) 2006; 80 T Brake (BFnrdp201686_CR48) 2005; 102 F Carozzi (BFnrdp201686_CR136) 2013; 14 FX Bosch (BFnrdp201686_CR198) 2016; 13 E Palmer (BFnrdp201686_CR34) 2014; 135 SL Giannini (BFnrdp201686_CR100) 2006; 24 S Vaccarella (BFnrdp201686_CR21) 2011; 204 Z Liu (BFnrdp201686_CR19) 2016; 13 MB Kovacic (BFnrdp201686_CR194) 2006; 66 N Egawa (BFnrdp201686_CR66) 2012; 86 C Valencia (BFnrdp201686_CR64) 2008; 128 CL Trimble (BFnrdp201686_CR90) 2010; 185 JM Palefsky (BFnrdp201686_CR107) 2011; 365 V Bouvard (BFnrdp201686_CR192) 2009; 10 MM Rietbergen (BFnrdp201686_CR51) 2014; 43 RA Mustafa (BFnrdp201686_CR199) 2016; 132 A Roman (BFnrdp201686_CR72) 2013; 445 A Duensing (BFnrdp201686_CR74) 2009; 50 SK Kjaer (BFnrdp201686_CR121) 2009; 2 RA Burger (BFnrdp201686_CR168) 1996; 88 SM Garland (BFnrdp201686_CR116) 2016; 63 ML Gillison (BFnrdp201686_CR35) 2012; 307 AR Kreimer (BFnrdp201686_CR197) 2015; 16 K Matthews (BFnrdp201686_CR86) 2003; 77 AJ Klingelhutz (BFnrdp201686_CR71) 2012; 424 S Schwartz (BFnrdp201686_CR56) 2013; 445 N Wentzensen (BFnrdp201686_CR149) 2015; 33 RG Pretorius (BFnrdp201686_CR148) 2004; 191 L Denny (BFnrdp201686_CR201) 2010; 102 JC Gage (BFnrdp201686_CR147) 2006; 108 J-D Combes (BFnrdp201686_CR16) 2014; 50 T Sperling (BFnrdp201686_CR85) 2012; 8 K Ganti (BFnrdp201686_CR73) 2015; 7 AR Giuliano (BFnrdp201686_CR117) 2015; 1 S Vaccarella (BFnrdp201686_CR10) 2014; 111 P Hubert (BFnrdp201686_CR95) 2014; 234 KK Ang (BFnrdp201686_CR177) 2010; 363 AR Kreimer (BFnrdp201686_CR18) 2013; 31 FX Bosch (BFnrdp201686_CR4) 2013; 31 SI Pai (BFnrdp201686_CR50) 2009; 4 H De Vuyst (BFnrdp201686_CR12) 2009; 124 J Fokom-Domgue (BFnrdp201686_CR200) 2015; 351 N Wentzensen (BFnrdp201686_CR133) 2015; 107 CM Hanson (BFnrdp201686_CR106) 2015; 3 N Wentzensen (BFnrdp201686_CR129) 2016; 76 K Sundström (BFnrdp201686_CR20) 2015; 107 M Plummer (BFnrdp201686_CR6) 2016; 4 PE Gravitt (BFnrdp201686_CR207) 2016; 213 H-U Bernard (BFnrdp201686_CR55) 2013; 445 N Santesso (BFnrdp201686_CR212) 2016; 132 MH Einstein (BFnrdp201686_CR101) 2011; 7 KU Petry (BFnrdp201686_CR152) 2016; 138 L Alemany (BFnrdp201686_CR11) 2015; 136 N Muñoz (BFnrdp201686_CR112) 2010; 102 MRE McCredie (BFnrdp201686_CR158) 2008; 9 KS Tewari (BFnrdp201686_CR165) 2014; 20 C de Martel (BFnrdp201686_CR14) 2015; 29 PS de Araujo-Souza (BFnrdp201686_CR23) 2014; 14 I Baussano (BFnrdp201686_CR206) 2016; 22 RS Kelly (BFnrdp201686_CR150) 2012; 119 S-H Chung (BFnrdp201686_CR46) 2010; 21 J Cuzick (BFnrdp201686_CR128) 2013; 108 N Wentzensen (BFnrdp201686_CR143) 2012; 104 M Schiffman (BFnrdp201686_CR157) 2016; 20 BJ Monk (BFnrdp201686_CR167) 2014; 32 G Ronco (BFnrdp201686_CR27) 2014; 383 M Herfs (BFnrdp201686_CR211) 2011; 19 KS Tewari (BFnrdp201686_CR166) 2014; 370 AR Giuliano (BFnrdp201686_CR102) 2011; 364 GA Maglennon (BFnrdp201686_CR93) 2014; 88 M Cremer (BFnrdp201686_CR203) 2016; 2 WK Huh (BFnrdp201686_CR125) 2015; 136 KP Garnock-Jones (BFnrdp201686_CR31) 2011; 71 E Isaacson Wechsler (BFnrdp201686_CR69) 2012; 86 CM Wheeler (BFnrdp201686_CR119) 2012; 13 GA Maglennon (BFnrdp201686_CR92) 2011; 414 K Canfell (BFnrdp201686_CR189) 2011; 29 C Bergeron (BFnrdp201686_CR131) 2015; 107 B Romanowski (BFnrdp201686_CR110) 2011; 7 N Vasiljevic (BFnrdp201686_CR140) 2014; 132 C Badoual (BFnrdp201686_CR185) 2013; 73 F-H Zhao (BFnrdp201686_CR145) 2013; 6 YL Woo (BFnrdp201686_CR87) 2008; 115 R van Baars (BFnrdp201686_CR146) 2015; 39 S Vinokurova (BFnrdp201686_CR76) 2008; 68 AR Giuliano (BFnrdp201686_CR28) 2008; 17 L Alemany (BFnrdp201686_CR13) 2016; 69 International Collaboration of Epidemiological Studies of Cervical Cancer (BFnrdp201686_CR37) 2006; 119 L Mirabello (BFnrdp201686_CR195) 2016; 108 |
| References_xml | – volume: 2 start-page: 868 year: 2009 end-page: 878 ident: CR121 article-title: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions publication-title: Cancer Prev. Res. (Phila.) doi: 10.1158/1940-6207.CAPR-09-0031 – volume: 30 start-page: F55 issue: Suppl. 5 year: 2012 end-page: F70 ident: CR52 article-title: The biology and life-cycle of human papillomaviruses publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.083 – volume: 365 start-page: 1576 year: 2011 end-page: 1585 ident: CR107 article-title: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1010971 – volume: 307 start-page: 693 year: 2012 end-page: 703 ident: CR35 article-title: Prevalence of oral HPV infection in the United States, 2009–2010 publication-title: JAMA doi: 10.1001/jama.2012.101 – volume: 53 start-page: 52 year: 2015 end-page: 59 ident: CR138 article-title: A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.02116-14 – volume: 8 start-page: e74797 year: 2013 ident: CR118 article-title: Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses publication-title: PLoS ONE doi: 10.1371/journal.pone.0074797 – volume: 48 start-page: 1191 year: 2012 end-page: 1201 ident: CR180 article-title: Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2012.06.019 – volume: 7 start-page: 1374 year: 2011 end-page: 1386 ident: CR110 article-title: Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study publication-title: Hum. Vaccin. doi: 10.4161/hv.7.12.18322 – volume: 372 start-page: 711 year: 2015 end-page: 723 ident: CR103 article-title: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1405044 – volume: 133 start-page: 2253 year: 2013 end-page: 2258 ident: CR59 article-title: Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with “low-risk” HPV genotypes 6 and 11 publication-title: Int. J. Cancer doi: 10.1002/ijc.28228 – volume: 28 start-page: 861 year: 2014 end-page: 867 ident: CR154 article-title: High-resolution anoscopy screening of HIV-positive MSM: longitudinal results from a pilot study publication-title: AIDS doi: 10.1097/QAD.0000000000000160 – volume: 13 start-page: 1003 year: 2008 end-page: 1017 ident: CR57 article-title: Papillomavirus E6 and E7 proteins and their cellular targets publication-title: Front. Biosci. doi: 10.2741/2739 – volume: 138 start-page: 2932 year: 2016 end-page: 2939 ident: CR152 article-title: Evaluating HPV-negative CIN2+ in the ATHENA trial publication-title: Int. J. Cancer doi: 10.1002/ijc.30032 – volume: 213 start-page: 1 year: 2016 end-page: 13 ident: CR81 article-title: Ubiquitin in the activation and attenuation of innate antiviral immunity publication-title: J. Exp. Med. doi: 10.1084/jem.20151531 – volume: 86 start-page: 6358 year: 2012 end-page: 6364 ident: CR69 article-title: Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression publication-title: J. Virol. doi: 10.1128/JVI.07069-11 – volume: 77 start-page: 8378 year: 2003 end-page: 8385 ident: CR86 article-title: Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin publication-title: J. Virol. doi: 10.1128/JVI.77.15.8378-8385.2003 – volume: 66 start-page: 10112 year: 2006 end-page: 10119 ident: CR194 article-title: Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-1812 – volume: 148 start-page: 34 year: 2008 end-page: 39 ident: CR63 article-title: Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection publication-title: J. Virol. Methods doi: 10.1016/j.jviromet.2007.10.005 – volume: 13 start-page: 847 year: 2015 end-page: 855 ident: CR187 article-title: Head and neck cancers, version 1. 2015 publication-title: J. Natl Compr. Canc. Netw. doi: 10.6004/jnccn.2015.0102 – volume: 29 start-page: 2487 year: 2011 end-page: 2494 ident: CR189 article-title: Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies publication-title: Vaccine doi: 10.1016/j.vaccine.2010.12.085 – volume: 108 start-page: 908 year: 2013 end-page: 913 ident: CR128 article-title: Comparing the performance of six human papillomavirus tests in a screening population publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.22 – ident: CR126 – volume: 31 start-page: 4550 year: 2013 end-page: 4559 ident: CR17 article-title: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.50.3870 – volume: 21 start-page: 504 year: 2010 end-page: 511 ident: CR46 article-title: Estrogen and ERα: culprits in cervical cancer? publication-title: Trends Endocrinol. Metab. doi: 10.1016/j.tem.2010.03.005 – volume: 131 start-page: 2349 year: 2012 end-page: 2359 ident: CR5 article-title: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.27485 – volume: 24 start-page: 771 year: 2004 end-page: 775 ident: CR209 article-title: Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell publication-title: Anticancer Res. – volume: 65 start-page: 139 year: 2015 end-page: 162 ident: CR173 article-title: Anal cancer: current standards in care and recent changes in practice publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21259 – volume: 119 start-page: 1108 year: 2006 end-page: 1124 ident: CR37 article-title: Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies publication-title: Int. J. Cancer doi: 10.1002/ijc.21953 – volume: 33 start-page: 3285 year: 2015 end-page: 3292 ident: CR186 article-title: Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3157 – volume: 368 start-page: 1706 year: 2006 end-page: 1728 ident: CR205 article-title: Sexual behaviour in context: a global perspective publication-title: Lancet doi: 10.1016/S0140-6736(06)69479-8 – volume: 30 start-page: F88 issue: Suppl. 5 year: 2012 end-page: F99 ident: CR123 article-title: Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.095 – volume: 30 start-page: F83 issue: Suppl. 5 year: 2012 end-page: F87 ident: CR99 article-title: Human papillomavirus vaccines — immune responses publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.106 – volume: 33 start-page: 83 year: 2015 end-page: 89 ident: CR149 article-title: Multiple biopsies and detection of cervical cancer precursors at colposcopy publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.55.9948 – volume: 309 start-page: 1793 year: 2013 end-page: 1802 ident: CR109 article-title: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.1625 – volume: 424 start-page: 77 year: 2012 end-page: 98 ident: CR71 article-title: Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses publication-title: Virology doi: 10.1016/j.virol.2011.12.018 – volume: 202 start-page: 1789 year: 2010 end-page: 1799 ident: CR24 article-title: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings publication-title: J. Infect. Dis. doi: 10.1086/657321 – volume: 370 start-page: 1609 year: 2007 end-page: 1621 ident: CR38 article-title: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies publication-title: Lancet doi: 10.1016/S0140-6736(07)61684-5 – ident: CR108 – volume: 28 start-page: 977 year: 2015 end-page: 993 ident: CR160 article-title: Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM publication-title: Mod. Pathol. doi: 10.1038/modpathol.2015.52 – volume: 13 start-page: 100 year: 2012 end-page: 110 ident: CR119 article-title: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70287-X – volume: 30 start-page: F123 issue: Suppl. 5 year: 2012 end-page: F138 ident: CR114 article-title: A review of clinical trials of human papillomavirus prophylactic vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.108 – volume: 25 start-page: 2952 year: 2007 end-page: 2965 ident: CR172 article-title: Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.10.8324 – volume: 13 start-page: 119 year: 2016 end-page: 132 ident: CR198 article-title: HPV-FASTER: broadening the scope for prevention of HPV-related cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2015.146 – volume: 21 start-page: 1542 year: 2012 end-page: 1546 ident: CR30 article-title: Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-12-0483 – volume: 13 start-page: 89 year: 2012 end-page: 99 ident: CR113 article-title: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70286-8 – volume: 106 start-page: dju153 year: 2014 ident: CR124 article-title: Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dju153 – volume: 14 start-page: 578 year: 2014 ident: CR23 article-title: Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig–McGill cohort study publication-title: BMC Infect. Dis. doi: 10.1186/s12879-014-0578-0 – volume: 14 start-page: 202 year: 2016 end-page: 212 ident: CR171 article-title: Chemoradiotherapy for anal squamous cell carcinoma publication-title: Surgeon doi: 10.1016/j.surge.2016.03.006 – volume: 105 start-page: 1550 year: 2013 end-page: 1557 ident: CR135 article-title: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djt235 – volume: 83 start-page: 2299 year: 2002 end-page: 2301 ident: CR91 article-title: Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination publication-title: J. Gen. Virol. doi: 10.1099/0022-1317-83-9-2299 – volume: 105 start-page: 28 year: 2011 end-page: 37 ident: CR111 article-title: End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.185 – volume: 100 start-page: 261 year: 2008 end-page: 269 ident: CR175 article-title: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djn011 – volume: 20 start-page: 5349 year: 2014 end-page: 5358 ident: CR165 article-title: New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1099 – volume: 7 start-page: e48954 year: 2012 ident: CR79 article-title: Transcriptional repression of E-cadherin by human papillomavirus type 16 E6 publication-title: PLoS ONE doi: 10.1371/journal.pone.0048954 – volume: 102 start-page: 1557 year: 2010 end-page: 1567 ident: CR201 article-title: Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq342 – volume: 89 start-page: 2866 year: 2015 end-page: 2874 ident: CR96 article-title: Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection publication-title: J. Virol. doi: 10.1128/JVI.02901-14 – volume: 88 start-page: 1361 year: 1996 end-page: 1368 ident: CR168 article-title: Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/88.19.1361 – volume: 32 start-page: S7 year: 2005 end-page: S15 ident: CR58 article-title: The papillomavirus life cycle publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2004.12.006 – volume: 24 start-page: 373 year: 2010 end-page: 379 ident: CR155 article-title: Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings publication-title: AIDS doi: 10.1097/QAD.0b013e328333ab8e – volume: 445 start-page: 138 year: 2013 end-page: 168 ident: CR72 article-title: The papillomavirus E7 proteins publication-title: Virology doi: 10.1016/j.virol.2013.04.013 – volume: 32 start-page: 76 year: 2013 end-page: 115 ident: CR196 article-title: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology publication-title: Int. J. Gynecol. Pathol. doi: 10.1097/PGP.0b013e31826916c7 – volume: 445 start-page: 197 year: 2013 end-page: 204 ident: CR55 article-title: Regulatory elements in the viral genome publication-title: Virology doi: 10.1016/j.virol.2013.04.035 – volume: 2 start-page: 11s year: 2016 end-page: 12s ident: CR203 article-title: Adapting CryoPen, a non-gas based cryotherapy system for use in low- and middle-income countries publication-title: J. Glob. Oncol. doi: 10.1200/JGO.2016.003947 – volume: 68 start-page: 307 year: 2008 end-page: 313 ident: CR76 article-title: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-2754 – volume: 33 start-page: 6892 year: 2015 end-page: 6901 ident: CR104 article-title: Immunogenicity and safety of the 9-valent HPV vaccine in men publication-title: Vaccine doi: 10.1016/j.vaccine.2015.06.088 – volume: 50 start-page: 370 year: 2014 end-page: 379 ident: CR16 article-title: Role of human papillomavirus in non-oropharyngeal head and neck cancers publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.11.004 – volume: 7 start-page: 3530 year: 2015 end-page: 3551 ident: CR73 article-title: The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy publication-title: Viruses doi: 10.3390/v7072785 – volume: 210 start-page: 1723 year: 2014 end-page: 1733 ident: CR94 article-title: Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiu330 – volume: 9 start-page: 425 year: 2008 end-page: 434 ident: CR158 article-title: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(08)70103-7 – volume: 50 start-page: 565 year: 2014 end-page: 574 ident: CR181 article-title: The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.09.008 – volume: 108 start-page: djw100 year: 2016 ident: CR195 article-title: HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djw100 – volume: 112 start-page: E3255 year: 2015 end-page: E3264 ident: CR47 article-title: Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1509322112 – volume: 2015 start-page: 32 year: 2015 end-page: 51 ident: CR1 article-title: Papillomaviruses: viral evolution, cancer and evolutionary medicine publication-title: Evol. Med. Public Health doi: 10.1093/emph/eov003 – volume: 445 start-page: 11 year: 2013 end-page: 20 ident: CR2 article-title: Evolution of the publication-title: Virology doi: 10.1016/j.virol.2013.05.012 – volume: 382 start-page: 889 year: 2013 end-page: 899 ident: CR9 article-title: Human papillomavirus and cervical cancer publication-title: Lancet doi: 10.1016/S0140-6736(13)60022-7 – volume: 104 start-page: 556 year: 2012 end-page: 565 ident: CR141 article-title: Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djs135 – volume: 128 start-page: 2894 year: 2008 end-page: 2903 ident: CR64 article-title: Human papillomavirus E6/E7 oncogenes promote mouse ear regeneration by increasing the rate of wound re-epithelization and epidermal growth publication-title: J. Invest. Dermatol. doi: 10.1038/jid.2008.156 – volume: 130 start-page: 595 year: 2013 end-page: 600 ident: CR144 article-title: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.06.005 – volume: 4 start-page: e609 year: 2016 end-page: e616 ident: CR6 article-title: Global burden of cancers attributable to infections in 2012: a synthetic analysis publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(16)30143-7 – volume: 108 start-page: djv403 year: 2016 ident: CR15 article-title: HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv403 – volume: 80 start-page: 4431 year: 2006 end-page: 4439 ident: CR65 article-title: Different modes of human papillomavirus DNA replication during maintenance publication-title: J. Virol. doi: 10.1128/JVI.80.9.4431-4439.2006 – volume: 10 start-page: 321 year: 2009 end-page: 322 ident: CR192 article-title: A review of human carcinogens — part B: biological agents publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(09)70096-8 – ident: CR105 – ident: CR122 – volume: 200 start-page: 1059 year: 2009 end-page: 1067 ident: CR29 article-title: Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004 publication-title: J. Infect. Dis. doi: 10.1086/604729 – volume: 107 start-page: dju423 year: 2015 ident: CR131 article-title: Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dju423 – volume: 7 start-page: 3863 year: 2015 end-page: 3890 ident: CR62 article-title: Human papillomaviruses; epithelial tropisms, and the development of neoplasia publication-title: Viruses doi: 10.3390/v7072802 – volume: 50 start-page: 364 year: 2014 end-page: 369 ident: CR33 article-title: Epidemiology of oral human papillomavirus infection publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.09.003 – volume: 118 start-page: 1481 year: 2006 end-page: 1495 ident: CR36 article-title: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies publication-title: Int. J. Cancer doi: 10.1002/ijc.21493 – volume: 43 start-page: 137 year: 2014 end-page: 142 ident: CR51 article-title: No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors publication-title: J. Oral Pathol. Med. doi: 10.1111/jop.12123 – volume: 15 start-page: 217 year: 2015 end-page: 230 ident: CR97 article-title: The role of sex hormones in immune protection of the female reproductive tract publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3819 – volume: 110 start-page: 525 year: 2006 end-page: 541 ident: CR54 article-title: Molecular biology of human papillomavirus infection and cervical cancer publication-title: Clin. Sci. (Lond.) doi: 10.1042/CS20050369 – volume: 102 start-page: 325 year: 2010 end-page: 339 ident: CR112 article-title: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djp534 – volume: 6 start-page: 938 year: 2013 end-page: 948 ident: CR145 article-title: An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China publication-title: Cancer Prev. Res. (Phila.) doi: 10.1158/1940-6207.CAPR-13-0091 – volume: 445 start-page: 115 year: 2013 end-page: 137 ident: CR70 article-title: Papillomavirus E6 oncoproteins publication-title: Virology doi: 10.1016/j.virol.2013.04.026 – volume: 108 start-page: 264 year: 2006 end-page: 272 ident: CR147 article-title: Number of cervical biopsies and sensitivity of colposcopy publication-title: Obstet. Gynecol. doi: 10.1097/01.AOG.0000220505.18525.85 – volume: 136 start-page: 178 year: 2015 end-page: 182 ident: CR125 article-title: Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.12.022 – volume: 370 start-page: 734 year: 2014 end-page: 743 ident: CR166 article-title: Improved survival with bevacizumab in advanced cervical cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1309748 – volume: 15 start-page: 565 year: 2015 end-page: 580 ident: CR115 article-title: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(14)71073-4 – ident: CR7 – volume: 7 start-page: 2485 year: 2015 end-page: 2506 ident: CR82 article-title: High-risk human papillomavirus targets crossroads in immune signaling publication-title: Viruses doi: 10.3390/v7052485 – volume: 63 start-page: 519 year: 2016 end-page: 527 ident: CR116 article-title: Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciw354 – volume: 90 start-page: 694 year: 2016 end-page: 704 ident: CR83 article-title: Interferon kappa inhibits human papillomavirus 31 transcription by inducing Sp100 proteins publication-title: J. Virol. doi: 10.1128/JVI.02137-15 – volume: 76 start-page: S49 year: 2016 end-page: S55 ident: CR129 article-title: Triage of HPV positive women in cervical cancer screening publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2015.11.015 – volume: 3 start-page: 408 year: 2015 end-page: 419 ident: CR106 article-title: Gavi HPV programs: application to implementation publication-title: Vaccines doi: 10.3390/vaccines3020408 – volume: 17 start-page: 2036 year: 2008 end-page: 2043 ident: CR28 article-title: The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-08-0151 – volume: 102 start-page: 2490 year: 2005 end-page: 2495 ident: CR48 article-title: Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0409883102 – volume: 9 start-page: 404 year: 2008 end-page: 406 ident: CR44 article-title: Heterogeneity in CIN3 diagnosis publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(08)70110-4 – volume: 73 start-page: 4791 year: 2013 end-page: 4800 ident: CR182 article-title: Enhanced radiation sensitivity in HPV-positive head and neck cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0587 – volume: 135 start-page: 2437 year: 2014 end-page: 2443 ident: CR34 article-title: Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions publication-title: Int. J. Cancer doi: 10.1002/ijc.28886 – volume: 20 start-page: 1 year: 2016 end-page: 7 ident: CR157 article-title: Suggested approach to simplify and improve cervical screening in the United States publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0000000000000170 – volume: 195 start-page: 1582 year: 2007 end-page: 1589 ident: CR25 article-title: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion publication-title: J. Infect. Dis. doi: 10.1086/516784 – volume: 19 start-page: 114 year: 2011 end-page: 120 ident: CR211 article-title: Mucosal junctions: open doors to HPV and HIV infections? publication-title: Trends Microbiol. doi: 10.1016/j.tim.2010.12.006 – volume: 11 start-page: 2286 year: 2006 end-page: 2302 ident: CR67 article-title: Papillomavirus genome structure, expression, and post-transcriptional regulation publication-title: Front. Biosci. doi: 10.2741/1971 – ident: CR8 – volume: 209 start-page: 855 year: 2014 end-page: 864 ident: CR22 article-title: No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study publication-title: J. Infect. Dis. doi: 10.1093/infdis/jit577 – volume: 3 start-page: 416 year: 2013 end-page: 421 ident: CR61 article-title: Latent papillomavirus infections and their regulation publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2013.06.003 – volume: 109 start-page: 10516 year: 2012 end-page: 10521 ident: CR161 article-title: A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1202684109 – volume: 150 start-page: 199 year: 2007 end-page: 209 ident: CR89 article-title: Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia publication-title: Clin. Exp. Immunol. doi: 10.1111/j.1365-2249.2007.03468.x – volume: 49 start-page: 3262 year: 2013 end-page: 3273 ident: CR42 article-title: Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.04.024 – volume: 31 start-page: H1 issue: Suppl. 7 year: 2013 end-page: H31 ident: CR4 article-title: Comprehensive control of human papillomavirus infections and related diseases publication-title: Vaccine doi: 10.1016/j.vaccine.2013.10.003 – volume: 136 start-page: 98 year: 2015 end-page: 107 ident: CR11 article-title: Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide publication-title: Int. J. Cancer doi: 10.1002/ijc.28963 – volume: 32 start-page: 2687 year: 2014 end-page: 2690 ident: CR167 article-title: Evidence-based therapy for recurrent cervical cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.8733 – volume: 123 start-page: 745 year: 2015 end-page: 754 ident: CR132 article-title: HPV DNA testing with cytology triage in cervical cancer screening: influence of revealing HPV infection status publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21596 – volume: 124 start-page: 1626 year: 2009 end-page: 1636 ident: CR12 article-title: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis publication-title: Int. J. Cancer doi: 10.1002/ijc.24116 – volume: 32 start-page: 3365 year: 2014 end-page: 3373 ident: CR176 article-title: Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.55.1937 – volume: 184 start-page: 530 year: 2014 end-page: 540 ident: CR49 article-title: Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2013.10.013 – volume: 86 start-page: 3276 year: 2012 end-page: 3283 ident: CR66 article-title: The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome publication-title: J. Virol. doi: 10.1128/JVI.06450-11 – volume: 123 start-page: 509 year: 2015 end-page: 510 ident: CR156 article-title: Screening to prevent anal cancer: current thinking and future directions publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21571 – volume: 348 start-page: g130 year: 2014 ident: CR120 article-title: Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial publication-title: BMJ doi: 10.1136/bmj.g130 – volume: 16 start-page: 290 year: 2012 end-page: 295 ident: CR153 article-title: 2011 terminology of the vulva of the International Federation for Cervical Pathology and Colposcopy publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31825934c7 – volume: 234 start-page: 464 year: 2014 end-page: 477 ident: CR95 article-title: Altered α-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment publication-title: J. Pathol. doi: 10.1002/path.4435 – volume: 124 start-page: 66 year: 2016 end-page: 67 ident: CR188 article-title: Why follow-back studies should be interpreted cautiously: the case of an HPV-negative cervical lesion publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21622 – volume: 60 start-page: 44 year: 2014 end-page: 49 ident: CR137 article-title: Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2014.02.002 – volume: 59 start-page: 161 year: 2014 end-page: 166 ident: CR142 article-title: A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2013.12.014 – volume: 119 start-page: 20 year: 2012 end-page: 25 ident: CR150 article-title: Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities publication-title: BJOG doi: 10.1111/j.1471-0528.2011.02970.x – volume: 370 start-page: 890 year: 2007 end-page: 907 ident: CR26 article-title: Human papillomavirus and cervical cancer publication-title: Lancet doi: 10.1016/S0140-6736(07)61416-0 – volume: 12 start-page: 281 year: 2009 end-page: 290 ident: CR191 article-title: Human papillomaviruses: genetic basis of carcinogenicity publication-title: Public Health Genomics doi: 10.1159/000214919 – volume: 113 start-page: 18 year: 2009 end-page: 25 ident: CR159 article-title: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0b013e31818f5008 – volume: 16 start-page: 775 year: 2015 end-page: 786 ident: CR197 article-title: Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00047-9 – volume: 12 start-page: 8 year: 2008 end-page: 10 ident: CR210 article-title: Why do human papillomavirus infections induce sharply demarcated lesions of the cervix? publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31806dba20 – ident: CR134 – volume: 446 start-page: 185 year: 2007 end-page: 189 ident: CR208 article-title: A single type of progenitor cell maintains normal epidermis publication-title: Nature doi: 10.1038/nature05574 – volume: 12 start-page: 1454 year: 2014 end-page: 1487 ident: CR174 article-title: Head and neck cancers, version 2. 2014. Clinical practice guidelines in oncology publication-title: J. Natl Compr. Canc. Netw. doi: 10.6004/jnccn.2014.0142 – volume: 25 start-page: 215 year: 2012 end-page: 222 ident: CR80 article-title: Epithelial cell responses to infection with human papillomavirus publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.05028-11 – volume: 50 start-page: 741 year: 2009 end-page: 747 ident: CR74 article-title: Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins publication-title: Environ. Mol. Mutagen. doi: 10.1002/em.20478 – volume: 111 start-page: 965 year: 2014 end-page: 969 ident: CR10 article-title: 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence publication-title: Br. J. Cancer doi: 10.1038/bjc.2014.362 – volume: 107 start-page: djv185 year: 2015 ident: CR20 article-title: Interactions between high- and low-risk HPV types reduce the risk of squamous cervical cancer publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv185 – volume: 64 start-page: 3878 year: 2004 end-page: 3884 ident: CR75 article-title: Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-0009 – volume: 88 start-page: 710 year: 2014 end-page: 716 ident: CR93 article-title: Immunosuppression facilitates the reactivation of latent papillomavirus infections publication-title: J. Virol. doi: 10.1128/JVI.02589-13 – volume: 122 start-page: 1380 year: 2016 end-page: 1387 ident: CR179 article-title: Rising population of survivors of oral squamous cell cancer in the United States publication-title: Cancer doi: 10.1002/cncr.29921 – volume: 13 start-page: 137 year: 2009 end-page: 144 ident: CR151 article-title: The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31819308d4 – volume: 36 start-page: e1 year: 2012 end-page: e72 ident: CR127 article-title: Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors publication-title: Epidemiol. Prev. – volume: 14 start-page: 168 year: 2013 end-page: 176 ident: CR136 article-title: Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70529-6 – volume: 386 start-page: 2078 year: 2015 end-page: 2088 ident: CR164 article-title: Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial publication-title: Lancet doi: 10.1016/S0140-6736(15)00239-1 – volume: 132 start-page: 252 year: 2016 end-page: 258 ident: CR212 article-title: World Health Organization guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer publication-title: Int. J. Gynaecol. Obstet. doi: 10.1016/j.ijgo.2015.07.038 – volume: 191 start-page: 430 year: 2004 end-page: 434 ident: CR148 article-title: Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2004.02.065 – volume: 67 start-page: 1067 year: 2014 end-page: 1071 ident: CR139 article-title: CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2014-202616 – volume: 26 start-page: 1650 year: 2007 end-page: 1655 ident: CR78 article-title: Viral oncoproteins target the DNA methyltransferases publication-title: Oncogene doi: 10.1038/sj.onc.1209950 – volume: 104 start-page: 1738 year: 2012 end-page: 1749 ident: CR143 article-title: Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djs425 – volume: 294 start-page: 63 year: 2015 end-page: 69 ident: CR98 article-title: Estrogen receptors regulate innate immune cells and signaling pathways publication-title: Cell. Immunol. doi: 10.1016/j.cellimm.2015.01.018 – volume: 132 start-page: 259 year: 2016 end-page: 265 ident: CR199 article-title: Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy publication-title: Int. J. Gynaecol. Obstet. doi: 10.1016/j.ijgo.2015.07.024 – volume: 29 start-page: 2173 year: 2015 end-page: 2181 ident: CR14 article-title: Cancers attributable to infections among adults with HIV in the United States publication-title: AIDS doi: 10.1097/QAD.0000000000000808 – volume: 39 start-page: 1518 year: 2015 end-page: 1528 ident: CR146 article-title: Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker panHPVE4 With P16INK4a publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000000498 – ident: CR163 – volume: 5 start-page: e1000318 year: 2009 ident: CR60 article-title: Establishment of human papillomavirus infection requires cell cycle progression publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1000318 – volume: 24 start-page: 5937 year: 2006 end-page: 5949 ident: CR100 article-title: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only publication-title: Vaccine doi: 10.1016/j.vaccine.2006.06.005 – volume: 364 start-page: 401 year: 2011 end-page: 411 ident: CR102 article-title: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0909537 – volume: 21 start-page: 111 year: 2012 end-page: 121 ident: CR41 article-title: Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-11-0664 – volume: 23 start-page: 1720 year: 2005 end-page: 1729 ident: CR84 article-title: Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells publication-title: Vaccine doi: 10.1016/j.vaccine.2004.09.035 – volume: 130 start-page: 2638 year: 2012 end-page: 2644 ident: CR45 article-title: Time since first sexual intercourse and the risk of cervical cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.26250 – volume: 138 start-page: 1453 year: 2016 end-page: 1461 ident: CR202 article-title: Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural China publication-title: Int. J. Cancer doi: 10.1002/ijc.29877 – volume: 69 start-page: 953 year: 2016 end-page: 961 ident: CR13 article-title: Role of human papillomavirus in penile carcinomas worldwide publication-title: Eur. Urol. doi: 10.1016/j.eururo.2015.12.007 – volume: 111 start-page: 1279 year: 2008 end-page: 1284 ident: CR130 article-title: Interobserver agreement in the assessment of components of colposcopic grading publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0b013e31816baed1 – volume: 383 start-page: 524 year: 2014 end-page: 532 ident: CR27 article-title: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials publication-title: Lancet doi: 10.1016/S0140-6736(13)62218-7 – volume: 71 start-page: 591 year: 2011 end-page: 602 ident: CR31 article-title: Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males publication-title: Drugs doi: 10.2165/11205980-000000000-00000 – volume: 111 start-page: 431 year: 2004 end-page: 439 ident: CR40 article-title: and invasive cervical cancer: a pooled analysis of the IARC multicentric case–control study publication-title: Int. J. Cancer doi: 10.1002/ijc.20257 – volume: 185 start-page: 7107 year: 2010 end-page: 7114 ident: CR90 article-title: Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium publication-title: J. Immunol. doi: 10.4049/jimmunol.1002756 – volume: 7 start-page: 1359 year: 2011 end-page: 1373 ident: CR101 article-title: Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years publication-title: Hum. Vaccin. doi: 10.4161/hv.7.12.18282 – volume: 1 start-page: 109 year: 2015 end-page: 115 ident: CR117 article-title: Seroconversion following anal and genital HPV infection in men: the HIM study publication-title: Papillomavirus Res. doi: 10.1016/j.pvr.2015.06.007 – volume: 443 start-page: 11 year: 2013 end-page: 19 ident: CR68 article-title: Regulation of the human papillomavirus type 16 late promoter by E7 and the cell cycle publication-title: Virology doi: 10.1016/j.virol.2013.04.033 – volume: 445 start-page: 187 year: 2013 end-page: 196 ident: CR56 article-title: Papillomavirus transcripts and posttranscriptional regulation publication-title: Virology doi: 10.1016/j.virol.2013.04.034 – volume: 4 start-page: 8 year: 2009 ident: CR193 article-title: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline publication-title: Infect. Agent. Cancer doi: 10.1186/1750-9378-4-8 – volume: 100 start-page: 513 year: 2008 end-page: 517 ident: CR3 article-title: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djn044 – volume: 132 start-page: 709 year: 2014 end-page: 714 ident: CR140 article-title: Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.02.001 – volume: 137 start-page: 893 year: 2015 end-page: 902 ident: CR190 article-title: The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador publication-title: Int. J. Cancer doi: 10.1002/ijc.29438 – volume: 363 start-page: 24 year: 2010 end-page: 35 ident: CR177 article-title: Human papillomavirus and survival of patients with oropharyngeal cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0912217 – volume: 107 start-page: djv257 year: 2015 ident: CR133 article-title: p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv257 – volume: 333 start-page: 1154 year: 2011 end-page: 1157 ident: CR183 article-title: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in publication-title: Science doi: 10.1126/science.1206923 – ident: CR169 – volume: 213 start-page: 723 year: 2016 end-page: 730 ident: CR207 article-title: Soil-transmitted helminth infections are associated with an increase in human papillomavirus prevalence and a T-helper type 2 cytokine signature in cervical fluids publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiv498 – year: 2016 ident: CR162 publication-title: Infect. Dis. – volume: 102 start-page: 1794 year: 2010 end-page: 1804 ident: CR39 article-title: and risk of prevalent and incident cervical premalignancy in a population-based cohort publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq436 – volume: 89 start-page: 275 year: 2002 end-page: 284 ident: CR88 article-title: The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development publication-title: Virus Res. doi: 10.1016/S0168-1702(02)00196-X – volume: 31 start-page: 2708 year: 2013 end-page: 2715 ident: CR18 article-title: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.47.2738 – volume: 10 start-page: 400 year: 2013 end-page: 410 ident: CR32 article-title: Clinical trials of human papillomavirus vaccines and beyond publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2013.84 – volume: 115 start-page: 1616 year: 2008 end-page: 1621 ident: CR87 article-title: Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis publication-title: BJOG doi: 10.1111/j.1471-0528.2008.01936.x – volume: 4 start-page: 49 year: 2009 end-page: 70 ident: CR50 article-title: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment publication-title: Annu. Rev. Pathol. doi: 10.1146/annurev.pathol.4.110807.092158 – volume: 22 start-page: 553 year: 2013 end-page: 560 ident: CR204 article-title: Human papillomavirus infection and the multistage carcinogenesis of cervical cancer publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-12-1406 – volume: 13 start-page: 10 year: 2016 end-page: 21 ident: CR19 article-title: Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration publication-title: Sex. Health doi: 10.1071/SH15089 – volume: 364 start-page: 249 year: 2004 end-page: 256 ident: CR43 article-title: The cervical cancer epidemic that screening has prevented in the UK publication-title: Lancet doi: 10.1016/S0140-6736(04)16674-9 – volume: 22 start-page: 18 year: 2016 end-page: 23 ident: CR206 article-title: Human papillomavirus vaccination at a time of changing sexual behavior publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2201.150791 – volume: 82 start-page: 5190 year: 2008 end-page: 5197 ident: CR53 article-title: Arrangement of L2 within the papillomavirus capsid publication-title: J. Virol. doi: 10.1128/JVI.02726-07 – volume: 89 start-page: 688 year: 2015 end-page: 702 ident: CR77 article-title: APOBEC3A functions as a restriction factor of human papillomavirus publication-title: J. Virol. doi: 10.1128/JVI.02383-14 – volume: 351 start-page: h3084 year: 2015 ident: CR200 article-title: Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies publication-title: BMJ doi: 10.1136/bmj.h3084 – volume: 204 start-page: 385 year: 2011 end-page: 390 ident: CR21 article-title: Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica publication-title: J. Infect. Dis. doi: 10.1093/infdis/jir286 – volume: 21 start-page: 320 year: 2016 end-page: 325 ident: CR170 article-title: Cervical cancer: screening, diagnosis and staging publication-title: J. BUON – volume: 8 start-page: e1002833 year: 2012 ident: CR85 article-title: Human papillomavirus type 8 interferes with a novel C/EBPβ-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1002833 – volume: 51 start-page: 982 year: 2015 end-page: 984 ident: CR178 article-title: Oropharyngeal cancer survivorship in Denmark, 1977–2012 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2015.08.006 – volume: 110 start-page: 489 year: 2014 end-page: 500 ident: CR184 article-title: Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.639 – volume: 73 start-page: 128 year: 2013 end-page: 138 ident: CR185 article-title: PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-2606 – volume: 414 start-page: 153 year: 2011 end-page: 163 ident: CR92 article-title: Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression publication-title: Virology doi: 10.1016/j.virol.2011.03.019 – ident: BFnrdp201686_CR126 – volume: 105 start-page: 28 year: 2011 ident: BFnrdp201686_CR111 publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.185 – volume: 115 start-page: 1616 year: 2008 ident: BFnrdp201686_CR87 publication-title: BJOG doi: 10.1111/j.1471-0528.2008.01936.x – volume: 3 start-page: 408 year: 2015 ident: BFnrdp201686_CR106 publication-title: Vaccines doi: 10.3390/vaccines3020408 – volume: 102 start-page: 2490 year: 2005 ident: BFnrdp201686_CR48 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0409883102 – volume: 414 start-page: 153 year: 2011 ident: BFnrdp201686_CR92 publication-title: Virology doi: 10.1016/j.virol.2011.03.019 – volume: 386 start-page: 2078 year: 2015 ident: BFnrdp201686_CR164 publication-title: Lancet doi: 10.1016/S0140-6736(15)00239-1 – volume: 86 start-page: 6358 year: 2012 ident: BFnrdp201686_CR69 publication-title: J. Virol. doi: 10.1128/JVI.07069-11 – volume: 112 start-page: E3255 year: 2015 ident: BFnrdp201686_CR47 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1509322112 – volume: 6 start-page: 938 year: 2013 ident: BFnrdp201686_CR145 publication-title: Cancer Prev. Res. (Phila.) doi: 10.1158/1940-6207.CAPR-13-0091 – volume: 65 start-page: 139 year: 2015 ident: BFnrdp201686_CR173 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21259 – volume: 89 start-page: 688 year: 2015 ident: BFnrdp201686_CR77 publication-title: J. Virol. doi: 10.1128/JVI.02383-14 – volume: 89 start-page: 275 year: 2002 ident: BFnrdp201686_CR88 publication-title: Virus Res. doi: 10.1016/S0168-1702(02)00196-X – volume: 21 start-page: 504 year: 2010 ident: BFnrdp201686_CR46 publication-title: Trends Endocrinol. Metab. doi: 10.1016/j.tem.2010.03.005 – volume: 33 start-page: 83 year: 2015 ident: BFnrdp201686_CR149 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.55.9948 – volume: 136 start-page: 98 year: 2015 ident: BFnrdp201686_CR11 publication-title: Int. J. Cancer doi: 10.1002/ijc.28963 – ident: BFnrdp201686_CR108 – volume: 36 start-page: e1 year: 2012 ident: BFnrdp201686_CR127 publication-title: Epidemiol. Prev. – volume: 107 start-page: dju423 year: 2015 ident: BFnrdp201686_CR131 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dju423 – volume: 29 start-page: 2173 year: 2015 ident: BFnrdp201686_CR14 publication-title: AIDS doi: 10.1097/QAD.0000000000000808 – ident: BFnrdp201686_CR134 doi: 10.1002/ijc.30456 – volume: 333 start-page: 1154 year: 2011 ident: BFnrdp201686_CR183 publication-title: Science doi: 10.1126/science.1206923 – volume: 210 start-page: 1723 year: 2014 ident: BFnrdp201686_CR94 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiu330 – volume: 124 start-page: 1626 year: 2009 ident: BFnrdp201686_CR12 publication-title: Int. J. Cancer doi: 10.1002/ijc.24116 – volume: 7 start-page: 3863 year: 2015 ident: BFnrdp201686_CR62 publication-title: Viruses doi: 10.3390/v7072802 – volume: 123 start-page: 745 year: 2015 ident: BFnrdp201686_CR132 publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21596 – volume: 309 start-page: 1793 year: 2013 ident: BFnrdp201686_CR109 publication-title: JAMA doi: 10.1001/jama.2013.1625 – volume: 14 start-page: 168 year: 2013 ident: BFnrdp201686_CR136 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70529-6 – volume: 200 start-page: 1059 year: 2009 ident: BFnrdp201686_CR29 publication-title: J. Infect. Dis. doi: 10.1086/604729 – volume: 364 start-page: 401 year: 2011 ident: BFnrdp201686_CR102 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0909537 – volume: 13 start-page: 119 year: 2016 ident: BFnrdp201686_CR198 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2015.146 – volume: 77 start-page: 8378 year: 2003 ident: BFnrdp201686_CR86 publication-title: J. Virol. doi: 10.1128/JVI.77.15.8378-8385.2003 – volume: 113 start-page: 18 year: 2009 ident: BFnrdp201686_CR159 publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0b013e31818f5008 – volume: 39 start-page: 1518 year: 2015 ident: BFnrdp201686_CR146 publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000000498 – volume: 22 start-page: 18 year: 2016 ident: BFnrdp201686_CR206 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2201.150791 – volume: 43 start-page: 137 year: 2014 ident: BFnrdp201686_CR51 publication-title: J. Oral Pathol. Med. doi: 10.1111/jop.12123 – volume: 80 start-page: 4431 year: 2006 ident: BFnrdp201686_CR65 publication-title: J. Virol. doi: 10.1128/JVI.80.9.4431-4439.2006 – volume: 13 start-page: 10 year: 2016 ident: BFnrdp201686_CR19 publication-title: Sex. Health doi: 10.1071/SH15089 – volume: 10 start-page: 321 year: 2009 ident: BFnrdp201686_CR192 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(09)70096-8 – volume: 111 start-page: 965 year: 2014 ident: BFnrdp201686_CR10 publication-title: Br. J. Cancer doi: 10.1038/bjc.2014.362 – volume: 69 start-page: 953 year: 2016 ident: BFnrdp201686_CR13 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2015.12.007 – volume: 24 start-page: 373 year: 2010 ident: BFnrdp201686_CR155 publication-title: AIDS doi: 10.1097/QAD.0b013e328333ab8e – volume: 443 start-page: 11 year: 2013 ident: BFnrdp201686_CR68 publication-title: Virology doi: 10.1016/j.virol.2013.04.033 – volume: 191 start-page: 430 year: 2004 ident: BFnrdp201686_CR148 publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2004.02.065 – volume: 22 start-page: 553 year: 2013 ident: BFnrdp201686_CR204 publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-12-1406 – volume: 13 start-page: 1003 year: 2008 ident: BFnrdp201686_CR57 publication-title: Front. Biosci. doi: 10.2741/2739 – volume: 86 start-page: 3276 year: 2012 ident: BFnrdp201686_CR66 publication-title: J. Virol. doi: 10.1128/JVI.06450-11 – volume: 5 start-page: e1000318 year: 2009 ident: BFnrdp201686_CR60 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1000318 – volume: 31 start-page: 4550 year: 2013 ident: BFnrdp201686_CR17 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.50.3870 – volume: 104 start-page: 556 year: 2012 ident: BFnrdp201686_CR141 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djs135 – volume: 13 start-page: 137 year: 2009 ident: BFnrdp201686_CR151 publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31819308d4 – volume: 33 start-page: 6892 year: 2015 ident: BFnrdp201686_CR104 publication-title: Vaccine doi: 10.1016/j.vaccine.2015.06.088 – volume: 110 start-page: 489 year: 2014 ident: BFnrdp201686_CR184 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.639 – volume: 8 start-page: e74797 year: 2013 ident: BFnrdp201686_CR118 publication-title: PLoS ONE doi: 10.1371/journal.pone.0074797 – volume: 185 start-page: 7107 year: 2010 ident: BFnrdp201686_CR90 publication-title: J. Immunol. doi: 10.4049/jimmunol.1002756 – volume: 13 start-page: 847 year: 2015 ident: BFnrdp201686_CR187 publication-title: J. Natl Compr. Canc. Netw. doi: 10.6004/jnccn.2015.0102 – volume: 108 start-page: djw100 year: 2016 ident: BFnrdp201686_CR195 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djw100 – volume: 33 start-page: 3285 year: 2015 ident: BFnrdp201686_CR186 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3157 – volume: 50 start-page: 370 year: 2014 ident: BFnrdp201686_CR16 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.11.004 – volume: 32 start-page: 76 year: 2013 ident: BFnrdp201686_CR196 publication-title: Int. J. Gynecol. Pathol. doi: 10.1097/PGP.0b013e31826916c7 – volume: 445 start-page: 187 year: 2013 ident: BFnrdp201686_CR56 publication-title: Virology doi: 10.1016/j.virol.2013.04.034 – volume: 7 start-page: 3530 year: 2015 ident: BFnrdp201686_CR73 publication-title: Viruses doi: 10.3390/v7072785 – ident: BFnrdp201686_CR122 – volume: 20 start-page: 5349 year: 2014 ident: BFnrdp201686_CR165 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1099 – volume: 13 start-page: 89 year: 2012 ident: BFnrdp201686_CR113 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70286-8 – volume: 122 start-page: 1380 year: 2016 ident: BFnrdp201686_CR179 publication-title: Cancer doi: 10.1002/cncr.29921 – volume: 118 start-page: 1481 year: 2006 ident: BFnrdp201686_CR36 publication-title: Int. J. Cancer doi: 10.1002/ijc.21493 – volume: 100 start-page: 513 year: 2008 ident: BFnrdp201686_CR3 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djn044 – volume: 4 start-page: 49 year: 2009 ident: BFnrdp201686_CR50 publication-title: Annu. Rev. Pathol. doi: 10.1146/annurev.pathol.4.110807.092158 – volume: 17 start-page: 2036 year: 2008 ident: BFnrdp201686_CR28 publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-08-0151 – volume: 31 start-page: 2708 year: 2013 ident: BFnrdp201686_CR18 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.47.2738 – volume: 123 start-page: 509 year: 2015 ident: BFnrdp201686_CR156 publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21571 – volume: 12 start-page: 281 year: 2009 ident: BFnrdp201686_CR191 publication-title: Public Health Genomics doi: 10.1159/000214919 – volume: 119 start-page: 20 year: 2012 ident: BFnrdp201686_CR150 publication-title: BJOG doi: 10.1111/j.1471-0528.2011.02970.x – volume: 445 start-page: 11 year: 2013 ident: BFnrdp201686_CR2 publication-title: Virology doi: 10.1016/j.virol.2013.05.012 – volume: 30 start-page: F55 issue: Suppl. 5 year: 2012 ident: BFnrdp201686_CR52 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.083 – volume: 73 start-page: 4791 year: 2013 ident: BFnrdp201686_CR182 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0587 – volume: 2015 start-page: 32 year: 2015 ident: BFnrdp201686_CR1 publication-title: Evol. Med. Public Health doi: 10.1093/emph/eov003 – volume: 109 start-page: 10516 year: 2012 ident: BFnrdp201686_CR161 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1202684109 – volume: 63 start-page: 519 year: 2016 ident: BFnrdp201686_CR116 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciw354 – volume: 370 start-page: 1609 year: 2007 ident: BFnrdp201686_CR38 publication-title: Lancet doi: 10.1016/S0140-6736(07)61684-5 – ident: BFnrdp201686_CR105 – volume: 21 start-page: 320 year: 2016 ident: BFnrdp201686_CR170 publication-title: J. BUON – volume: 7 start-page: 1374 year: 2011 ident: BFnrdp201686_CR110 publication-title: Hum. Vaccin. doi: 10.4161/hv.7.12.18322 – volume: 132 start-page: 709 year: 2014 ident: BFnrdp201686_CR140 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.02.001 – volume: 3 start-page: 416 year: 2013 ident: BFnrdp201686_CR61 publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2013.06.003 – volume: 7 start-page: e48954 year: 2012 ident: BFnrdp201686_CR79 publication-title: PLoS ONE doi: 10.1371/journal.pone.0048954 – volume: 213 start-page: 723 year: 2016 ident: BFnrdp201686_CR207 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiv498 – volume: 14 start-page: 578 year: 2014 ident: BFnrdp201686_CR23 publication-title: BMC Infect. Dis. doi: 10.1186/s12879-014-0578-0 – volume: 12 start-page: 8 year: 2008 ident: BFnrdp201686_CR210 publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31806dba20 – volume: 28 start-page: 861 year: 2014 ident: BFnrdp201686_CR154 publication-title: AIDS doi: 10.1097/QAD.0000000000000160 – volume-title: Infect. Dis. year: 2016 ident: BFnrdp201686_CR162 doi: 10.1016/S1473-3099(16)30116-5 – volume: 108 start-page: djv403 year: 2016 ident: BFnrdp201686_CR15 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv403 – volume: 9 start-page: 425 year: 2008 ident: BFnrdp201686_CR158 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(08)70103-7 – volume: 368 start-page: 1706 year: 2006 ident: BFnrdp201686_CR205 publication-title: Lancet doi: 10.1016/S0140-6736(06)69479-8 – volume: 106 start-page: dju153 year: 2014 ident: BFnrdp201686_CR124 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dju153 – volume: 12 start-page: 1454 year: 2014 ident: BFnrdp201686_CR174 publication-title: J. Natl Compr. Canc. Netw. doi: 10.6004/jnccn.2014.0142 – volume: 348 start-page: g130 year: 2014 ident: BFnrdp201686_CR120 publication-title: BMJ doi: 10.1136/bmj.g130 – volume: 102 start-page: 1794 year: 2010 ident: BFnrdp201686_CR39 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq436 – volume: 204 start-page: 385 year: 2011 ident: BFnrdp201686_CR21 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jir286 – volume: 130 start-page: 2638 year: 2012 ident: BFnrdp201686_CR45 publication-title: Int. J. Cancer doi: 10.1002/ijc.26250 – volume: 32 start-page: 2687 year: 2014 ident: BFnrdp201686_CR167 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.8733 – volume: 16 start-page: 775 year: 2015 ident: BFnrdp201686_CR197 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00047-9 – volume: 2 start-page: 868 year: 2009 ident: BFnrdp201686_CR121 publication-title: Cancer Prev. Res. (Phila.) doi: 10.1158/1940-6207.CAPR-09-0031 – volume: 382 start-page: 889 year: 2013 ident: BFnrdp201686_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(13)60022-7 – volume: 445 start-page: 115 year: 2013 ident: BFnrdp201686_CR70 publication-title: Virology doi: 10.1016/j.virol.2013.04.026 – volume: 82 start-page: 5190 year: 2008 ident: BFnrdp201686_CR53 publication-title: J. Virol. doi: 10.1128/JVI.02726-07 – volume: 29 start-page: 2487 year: 2011 ident: BFnrdp201686_CR189 publication-title: Vaccine doi: 10.1016/j.vaccine.2010.12.085 – volume: 111 start-page: 431 year: 2004 ident: BFnrdp201686_CR40 publication-title: Int. J. Cancer doi: 10.1002/ijc.20257 – volume: 7 start-page: 2485 year: 2015 ident: BFnrdp201686_CR82 publication-title: Viruses doi: 10.3390/v7052485 – volume: 30 start-page: F83 issue: Suppl. 5 year: 2012 ident: BFnrdp201686_CR99 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.106 – volume: 50 start-page: 741 year: 2009 ident: BFnrdp201686_CR74 publication-title: Environ. Mol. Mutagen. doi: 10.1002/em.20478 – volume: 307 start-page: 693 year: 2012 ident: BFnrdp201686_CR35 publication-title: JAMA doi: 10.1001/jama.2012.101 – volume: 23 start-page: 1720 year: 2005 ident: BFnrdp201686_CR84 publication-title: Vaccine doi: 10.1016/j.vaccine.2004.09.035 – volume: 2 start-page: 11s year: 2016 ident: BFnrdp201686_CR203 publication-title: J. Glob. Oncol. doi: 10.1200/JGO.2016.003947 – volume: 363 start-page: 24 year: 2010 ident: BFnrdp201686_CR177 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0912217 – volume: 105 start-page: 1550 year: 2013 ident: BFnrdp201686_CR135 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djt235 – volume: 9 start-page: 404 year: 2008 ident: BFnrdp201686_CR44 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(08)70110-4 – volume: 107 start-page: djv257 year: 2015 ident: BFnrdp201686_CR133 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv257 – volume: 137 start-page: 893 year: 2015 ident: BFnrdp201686_CR190 publication-title: Int. J. Cancer doi: 10.1002/ijc.29438 – volume: 89 start-page: 2866 year: 2015 ident: BFnrdp201686_CR96 publication-title: J. Virol. doi: 10.1128/JVI.02901-14 – volume: 64 start-page: 3878 year: 2004 ident: BFnrdp201686_CR75 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-0009 – volume: 25 start-page: 2952 year: 2007 ident: BFnrdp201686_CR172 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.10.8324 – volume: 132 start-page: 259 year: 2016 ident: BFnrdp201686_CR199 publication-title: Int. J. Gynaecol. Obstet. doi: 10.1016/j.ijgo.2015.07.024 – volume: 50 start-page: 364 year: 2014 ident: BFnrdp201686_CR33 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.09.003 – volume: 124 start-page: 66 year: 2016 ident: BFnrdp201686_CR188 publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21622 – volume: 294 start-page: 63 year: 2015 ident: BFnrdp201686_CR98 publication-title: Cell. Immunol. doi: 10.1016/j.cellimm.2015.01.018 – volume: 24 start-page: 771 year: 2004 ident: BFnrdp201686_CR209 publication-title: Anticancer Res. – volume: 7 start-page: 1359 year: 2011 ident: BFnrdp201686_CR101 publication-title: Hum. Vaccin. doi: 10.4161/hv.7.12.18282 – volume: 67 start-page: 1067 year: 2014 ident: BFnrdp201686_CR139 publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2014-202616 – volume: 88 start-page: 1361 year: 1996 ident: BFnrdp201686_CR168 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/88.19.1361 – volume: 130 start-page: 595 year: 2013 ident: BFnrdp201686_CR144 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.06.005 – volume: 132 start-page: 252 year: 2016 ident: BFnrdp201686_CR212 publication-title: Int. J. Gynaecol. Obstet. doi: 10.1016/j.ijgo.2015.07.038 – volume: 131 start-page: 2349 year: 2012 ident: BFnrdp201686_CR5 publication-title: Int. J. Cancer doi: 10.1002/ijc.27485 – volume: 60 start-page: 44 year: 2014 ident: BFnrdp201686_CR137 publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2014.02.002 – volume: 51 start-page: 982 year: 2015 ident: BFnrdp201686_CR178 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2015.08.006 – volume: 76 start-page: S49 year: 2016 ident: BFnrdp201686_CR129 publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2015.11.015 – volume: 90 start-page: 694 year: 2016 ident: BFnrdp201686_CR83 publication-title: J. Virol. doi: 10.1128/JVI.02137-15 – volume: 66 start-page: 10112 year: 2006 ident: BFnrdp201686_CR194 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-1812 – volume: 184 start-page: 530 year: 2014 ident: BFnrdp201686_CR49 publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2013.10.013 – volume: 59 start-page: 161 year: 2014 ident: BFnrdp201686_CR142 publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2013.12.014 – volume: 11 start-page: 2286 year: 2006 ident: BFnrdp201686_CR67 publication-title: Front. Biosci. doi: 10.2741/1971 – volume: 26 start-page: 1650 year: 2007 ident: BFnrdp201686_CR78 publication-title: Oncogene doi: 10.1038/sj.onc.1209950 – volume: 372 start-page: 711 year: 2015 ident: BFnrdp201686_CR103 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1405044 – volume: 31 start-page: H1 issue: Suppl. 7 year: 2013 ident: BFnrdp201686_CR4 publication-title: Vaccine doi: 10.1016/j.vaccine.2013.10.003 – volume: 71 start-page: 591 year: 2011 ident: BFnrdp201686_CR31 publication-title: Drugs doi: 10.2165/11205980-000000000-00000 – volume: 110 start-page: 525 year: 2006 ident: BFnrdp201686_CR54 publication-title: Clin. Sci. (Lond.) doi: 10.1042/CS20050369 – ident: BFnrdp201686_CR8 – volume: 104 start-page: 1738 year: 2012 ident: BFnrdp201686_CR143 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djs425 – volume: 119 start-page: 1108 year: 2006 ident: BFnrdp201686_CR37 publication-title: Int. J. Cancer doi: 10.1002/ijc.21953 – volume: 28 start-page: 977 year: 2015 ident: BFnrdp201686_CR160 publication-title: Mod. Pathol. doi: 10.1038/modpathol.2015.52 – volume: 138 start-page: 2932 year: 2016 ident: BFnrdp201686_CR152 publication-title: Int. J. Cancer doi: 10.1002/ijc.30032 – volume: 102 start-page: 1557 year: 2010 ident: BFnrdp201686_CR201 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq342 – volume: 108 start-page: 908 year: 2013 ident: BFnrdp201686_CR128 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.22 – volume: 20 start-page: 1 year: 2016 ident: BFnrdp201686_CR157 publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0000000000000170 – volume: 19 start-page: 114 year: 2011 ident: BFnrdp201686_CR211 publication-title: Trends Microbiol. doi: 10.1016/j.tim.2010.12.006 – volume: 15 start-page: 217 year: 2015 ident: BFnrdp201686_CR97 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3819 – volume: 4 start-page: 8 year: 2009 ident: BFnrdp201686_CR193 publication-title: Infect. Agent. Cancer doi: 10.1186/1750-9378-4-8 – ident: BFnrdp201686_CR7 – volume: 195 start-page: 1582 year: 2007 ident: BFnrdp201686_CR25 publication-title: J. Infect. Dis. doi: 10.1086/516784 – volume: 21 start-page: 111 year: 2012 ident: BFnrdp201686_CR41 publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-11-0664 – volume: 102 start-page: 325 year: 2010 ident: BFnrdp201686_CR112 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djp534 – volume: 135 start-page: 2437 year: 2014 ident: BFnrdp201686_CR34 publication-title: Int. J. Cancer doi: 10.1002/ijc.28886 – volume: 83 start-page: 2299 year: 2002 ident: BFnrdp201686_CR91 publication-title: J. Gen. Virol. doi: 10.1099/0022-1317-83-9-2299 – volume: 16 start-page: 290 year: 2012 ident: BFnrdp201686_CR153 publication-title: J. Low. Genit. Tract Dis. doi: 10.1097/LGT.0b013e31825934c7 – volume: 73 start-page: 128 year: 2013 ident: BFnrdp201686_CR185 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-2606 – volume: 370 start-page: 734 year: 2014 ident: BFnrdp201686_CR166 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1309748 – volume: 50 start-page: 565 year: 2014 ident: BFnrdp201686_CR181 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2013.09.008 – volume: 424 start-page: 77 year: 2012 ident: BFnrdp201686_CR71 publication-title: Virology doi: 10.1016/j.virol.2011.12.018 – volume: 30 start-page: F123 issue: Suppl. 5 year: 2012 ident: BFnrdp201686_CR114 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.108 – volume: 133 start-page: 2253 year: 2013 ident: BFnrdp201686_CR59 publication-title: Int. J. Cancer doi: 10.1002/ijc.28228 – volume: 148 start-page: 34 year: 2008 ident: BFnrdp201686_CR63 publication-title: J. Virol. Methods doi: 10.1016/j.jviromet.2007.10.005 – volume: 213 start-page: 1 year: 2016 ident: BFnrdp201686_CR81 publication-title: J. Exp. Med. doi: 10.1084/jem.20151531 – volume: 202 start-page: 1789 year: 2010 ident: BFnrdp201686_CR24 publication-title: J. Infect. Dis. doi: 10.1086/657321 – volume: 4 start-page: e609 year: 2016 ident: BFnrdp201686_CR6 publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(16)30143-7 – volume: 364 start-page: 249 year: 2004 ident: BFnrdp201686_CR43 publication-title: Lancet doi: 10.1016/S0140-6736(04)16674-9 – volume: 136 start-page: 178 year: 2015 ident: BFnrdp201686_CR125 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.12.022 – volume: 32 start-page: S7 year: 2005 ident: BFnrdp201686_CR58 publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2004.12.006 – volume: 107 start-page: djv185 year: 2015 ident: BFnrdp201686_CR20 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djv185 – ident: BFnrdp201686_CR163 – volume: 24 start-page: 5937 year: 2006 ident: BFnrdp201686_CR100 publication-title: Vaccine doi: 10.1016/j.vaccine.2006.06.005 – volume: 209 start-page: 855 year: 2014 ident: BFnrdp201686_CR22 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jit577 – volume: 25 start-page: 215 year: 2012 ident: BFnrdp201686_CR80 publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.05028-11 – volume: 370 start-page: 890 year: 2007 ident: BFnrdp201686_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(07)61416-0 – volume: 49 start-page: 3262 year: 2013 ident: BFnrdp201686_CR42 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.04.024 – volume: 108 start-page: 264 year: 2006 ident: BFnrdp201686_CR147 publication-title: Obstet. Gynecol. doi: 10.1097/01.AOG.0000220505.18525.85 – volume: 13 start-page: 100 year: 2012 ident: BFnrdp201686_CR119 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70287-X – volume: 351 start-page: h3084 year: 2015 ident: BFnrdp201686_CR200 publication-title: BMJ doi: 10.1136/bmj.h3084 – volume: 1 start-page: 109 year: 2015 ident: BFnrdp201686_CR117 publication-title: Papillomavirus Res. doi: 10.1016/j.pvr.2015.06.007 – volume: 68 start-page: 307 year: 2008 ident: BFnrdp201686_CR76 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-2754 – volume: 53 start-page: 52 year: 2015 ident: BFnrdp201686_CR138 publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.02116-14 – volume: 88 start-page: 710 year: 2014 ident: BFnrdp201686_CR93 publication-title: J. Virol. doi: 10.1128/JVI.02589-13 – volume: 111 start-page: 1279 year: 2008 ident: BFnrdp201686_CR130 publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0b013e31816baed1 – volume: 14 start-page: 202 year: 2016 ident: BFnrdp201686_CR171 publication-title: Surgeon doi: 10.1016/j.surge.2016.03.006 – volume: 48 start-page: 1191 year: 2012 ident: BFnrdp201686_CR180 publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2012.06.019 – volume: 30 start-page: F88 issue: Suppl. 5 year: 2012 ident: BFnrdp201686_CR123 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.095 – volume: 32 start-page: 3365 year: 2014 ident: BFnrdp201686_CR176 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.55.1937 – volume: 365 start-page: 1576 year: 2011 ident: BFnrdp201686_CR107 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1010971 – volume: 21 start-page: 1542 year: 2012 ident: BFnrdp201686_CR30 publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-12-0483 – volume: 138 start-page: 1453 year: 2016 ident: BFnrdp201686_CR202 publication-title: Int. J. Cancer doi: 10.1002/ijc.29877 – volume: 234 start-page: 464 year: 2014 ident: BFnrdp201686_CR95 publication-title: J. Pathol. doi: 10.1002/path.4435 – volume: 445 start-page: 197 year: 2013 ident: BFnrdp201686_CR55 publication-title: Virology doi: 10.1016/j.virol.2013.04.035 – volume: 383 start-page: 524 year: 2014 ident: BFnrdp201686_CR27 publication-title: Lancet doi: 10.1016/S0140-6736(13)62218-7 – volume: 150 start-page: 199 year: 2007 ident: BFnrdp201686_CR89 publication-title: Clin. Exp. Immunol. doi: 10.1111/j.1365-2249.2007.03468.x – volume: 8 start-page: e1002833 year: 2012 ident: BFnrdp201686_CR85 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1002833 – volume: 128 start-page: 2894 year: 2008 ident: BFnrdp201686_CR64 publication-title: J. Invest. Dermatol. doi: 10.1038/jid.2008.156 – volume: 445 start-page: 138 year: 2013 ident: BFnrdp201686_CR72 publication-title: Virology doi: 10.1016/j.virol.2013.04.013 – ident: BFnrdp201686_CR169 – volume: 100 start-page: 261 year: 2008 ident: BFnrdp201686_CR175 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djn011 – volume: 10 start-page: 400 year: 2013 ident: BFnrdp201686_CR32 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2013.84 – volume: 446 start-page: 185 year: 2007 ident: BFnrdp201686_CR208 publication-title: Nature doi: 10.1038/nature05574 – volume: 15 start-page: 565 year: 2015 ident: BFnrdp201686_CR115 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(14)71073-4 |
| SSID | ssj0001586986 |
| Score | 2.5625932 |
| SecondaryResourceType | review_article |
| Snippet | Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 16086 |
| SubjectTerms | 631/326/590 631/326/596/2560 692/4028/67/1517/1371 692/699/1503/1298/1299 692/699/67/1536/1665 Cancer Cancer Research Carcinogens Cervical cancer Early Detection of Cancer - methods Epidemiology Female Head & neck cancer Human papillomavirus Humans Immunization Incidence Infections Internal Medicine Male Mass Screening - methods Mass Screening - standards Medical Microbiology Medical screening Medicine Medicine & Public Health Papillomaviridae - immunology Papillomaviridae - pathogenicity Papillomavirus Infections - complications Papillomavirus Infections - epidemiology Papillomavirus Infections - physiopathology Papillomavirus Vaccines - immunology Papillomavirus Vaccines - therapeutic use primer Quality of Life Research Throat cancer Uterine Cervical Neoplasms - etiology Uterine Cervical Neoplasms - prevention & control Vaccines |
| Title | Carcinogenic human papillomavirus infection |
| URI | https://link.springer.com/article/10.1038/nrdp.2016.86 https://www.ncbi.nlm.nih.gov/pubmed/27905473 https://www.proquest.com/docview/2711097004 https://www.proquest.com/docview/1845252572 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_8APFF_LY6RwUVRaptkybpk-hQRNgQUdhbaT4Kg9nObvPvN2nTTZj63KM97q65S36X3wGc8pj6WESZRxmJPSyo8nQaEh6WLAsjgQJZAe3dHnl6x8_9qG8P3Ma2rbJZE6uFWhbCnJHfhNRwYxoy9tvRp2emRhl01Y7QWIbVirpMxzPt0_kZS6QVYMT2u_uI3eSlNCSVAbk2l6d_ZqKF8nIBGq0yzuMmbNhS0b2rfbsFSyrfhrWuBcN3AHfMHKC80CEwEG41bM8dpaPBcFh8pF-Dcjp2m1ar3L14MTz-5eUuvD8-vHWePDsEwRO60pl4WSS5rilwpHyVxb4iihDBAyZjKrMA8UCSMOCIZDTkJBaYZDHlyFcYccVxqNAerORFrg7AlYzIOCOB9hrFBKVpzNJUb4-lTtERR9yBq8YgibAM4WZQxTCpkGrEEmO-xJgvYcSBs5n0qGbG-EOu1dg2sf_HOJl704GT2WMd2QauSHNVTMeJ3ntGoSFrDR3Yr30y-1BoeMUwRQ6cN06av_w3LQ7_1-II1o1g3afSgpVJOVXHutqY8HYVUm1YvX_ovbx-A5EC1Ug |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQS9oPJsoIUgUQRCoYnt2M4BISittrS7qlAr9WbiR6SVlmTZB4g_1d9YTx67SAVuPcdxnJmxZ-wZfx_AS52JmJm0iITkWcSMcJF3QyZiVhYkNTSxdaJ9MOT9c_blIr1Yg8vuLgyWVXZrYr1Q28rgGfkeEYiNiWDsHyY_ImSNwuxqR6HRmMWx-_3Lb9lm748-e_3uEnJ4cLbfj1pWgcj40GEeFanV3kmz1MWuyGLHHedGJ9JmwhYJ1YnlJNGUF4JonhnGi0xoGjtGtdOMOOr7vQXrDG-09mD908Hw9OvqVCf1vyx5W2EfU7lXTi3CYib8HV7X_tP3XQtoryVjax93uAl32-A0_NhY0z1Yc-V9uD1o0-8PgO0j81BZeaMbmbCm9wsn-WQ0Hlff85-j6WIWdsVdZfj6FJkDpm8ewvmNCOgR9MqqdFsQWsltVvDE24lgnOZ5JvPcb8itDwpSTXUAbzuBKNNikiM1xljVuXEqFYpPofiU5AHsLltPGiyOf7Tb7mSr2hk5Uyv7CeDF8rGfS5ggyUtXLWbK73ZTgvCwJIDHjU6WHyKIZMYEDeBVp6RV538bxZP_j-I53OmfDU7UydHw-Cls4EtNlcw29ObThdvxsc5cP2sNLIRvN23TV53EEq4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carcinogenic+human+papillomavirus+infection+%28Primer%29&rft.jtitle=Nature+reviews.+Disease+primers&rft.au=Schiffman%2C+Mark&rft.au=Doorbar%2C+John&rft.au=Wentzensen%2C+Nicolas&rft.au=de+Sanjos%C3%A9%2C+Silvia&rft.date=2016-12-01&rft.pub=Nature+Publishing+Group&rft.eissn=2056-676X&rft.volume=2&rft.issue=1&rft_id=info:doi/10.1038%2Fnrdp.2016.86 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-676X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-676X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-676X&client=summon |